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A B S T R A C T
Clinical trials identiﬁed intravitreal vascular endothelial growth factor inhibitors (anti-VEGF agents) have the
potential to stabilise or even improve visual acuity outcomes in neovascular age-related macular degeneration
(AMD), a sight-threatening disease. Real-world evidence allows us to assess whether results from randomised
controlled trials can be applied to the general population. We describe the development of global registries, in
particular the Fight Retinal Blindness! registry that originated in Australia, the United Kingdom AMD Electronic
Medical Records User Group and the IRIS registry in the USA. Real-world observations relating to eﬃcacy, safety
and resource utilisation of intravitreal anti-VEGF therapy for neovascular AMD are then summarised. Novel
observations that would have been challenging to identify in a clinical trial setting are then highlighted, in-
cluding the risk of late disease reactivation, outcomes in second versus ﬁrst treated eyes, and the increased risk of
posterior capsular rupture during cataract surgery in patients who have received intravitreal anti-VEGF therapy.
We conclude by exploring future directions in the ﬁeld. This includes the development of a global consensus on
real-world outcome measures to allow greater comparison of results. Real-world neovascular AMD outcome
registries can be linked with other databases to determine systemic safety or genetic predictors of treatment
eﬃcacy. Machine learning oﬀers opportunities to extract useful insights from “Big Data” often collected in these
registries. Real-world registries could be used by drug regulatory authorities and industry as an alternative to
more costly and time-consuming phase 4 clinical trials, potentially allowing medication costs to be based on
outcomes achieved.
1. Introduction
1.1. Natural history of neovascular age-related macular degeneration and
poor prognosis with historic interventions
Age-related macular degeneration (AMD) is a leading cause of ir-
reversible visual loss in developed countries and accounts for 7% of
global blindness worldwide (Bourne et al., 2013; Bressler, 2004). The
worldwide prevalence of AMD is rising as the population ages, with 288
million people projected to have either the early or late manifestations
of AMD by 2040 (Wong et al., 2014). Late disease is characterised by
signiﬁcant loss of central vision gradually due to geographic atrophy or
more rapidly due to development of neovascularisation.
Neovascular (exudative or wet) AMD is characterised by aberrant
angiogenesis originating from the choroidal or, less frequently, the
retinal circulation (Gass et al., 2003). These aberrant vessels are prone
to leakage resulting in ﬂuid accumulation, haemorrhage and ﬁbrosis
that can lead to rapid central visual loss compared with atrophic AMD
which causes more gradual visual decline. Whilst it occurs in less than
15% of all patients with AMD, neovascular AMD was, at least before the
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advent of vascular endothelial growth factor (VEGF) inhibitors, the
cause of over 80% of cases of blind registration (Jager et al., 2008).
The Macular Photocoagulation Study (MPS) (1982) evaluated laser
photocoagulation for the management of neovascular AMD. Initially,
patients with choroidal neovascular membranes outside the fovea (ex-
trafoveal) were recruited. After 18 months of follow-up, 60% of un-
treated eyes versus 25% of treated eyes had experienced severe visual
loss (deﬁned as loss of six or more letters on a logarithm of the
minimum angle of resolution [LogMAR] vision chart) and further re-
cruitment was stopped as there was now clinical trial evidence that a
treatment for extrafoveal neovascular AMD could reduce the risk of
severe visual loss. However, after 3 years of follow-up, over half (59%)
of eyes had recurrent choroidal neovascularisation documented. The
MPS Group proceeded to assess laser photocoagulation for neovascular
AMD lesions under the fovea (subfoveal) (1991). Even though there
were larger losses in vision at 3 months in treated eyes, by 2 years only
21% of treated versus 38% of untreated eyes experienced severe visual
loss. The MPS Group also observed that neovascular AMD developed in
fellow eyes at a rate of approximately 5% per year during 5 years
follow-up (1993).
Several other treatments for neovascular AMD have failed evalua-
tion in randomised controlled trials. The Submacular Surgery Trials
research group reported that surgery for subfoveal lesions in neovas-
cular AMD as performed in the clinical trial did not improve or preserve
visual acuity compared with observation over 2 years and therefore was
not recommended for patients with similar lesions (Hawkins et al.,
2004). A single dose of intravitreal triamcinolone had no eﬀect on the
risk of loss of visual acuity over 1 year in study eyes with neovascular
AMD although there was a reduction in angiographic leakage at 3
months (Gillies et al., 2003). A Cochrane Review (Evans et al., 2010) of
trials of external beam and plaque radiotherapy for neovascular AMD
did not identify convincing evidence that radiotherapy on its own was
an eﬀective treatment.
Clinical trials with verteporﬁn photodynamic therapy (cold laser
plus sensitising dye) were initiated in 1996. The Treatment of AMD
with Photodynamic (TAP) Study (Bressler, 2002) reported 59% of eyes
with predominantly classic subfoveal lesions in the verteporﬁn group
versus 31% of eyes in the placebo group lost fewer than 15 letters vision
from baseline over 2 years. The Verteporﬁn in Photodynamic Therapy
(VIP) Study (Verteporﬁn In Photodynamic Therapy Study, 2001) re-
ported 45% of eyes with occult lesions with no classic component
versus 32% of eyes in the placebo group lost fewer than 15 letters of
vision from baseline over 2 years.
The results of the clinical trials discussed above demonstrated that
there was a major unmet need for eﬀective treatments for neovascular
AMD that could stabilise disease and potentially improve vision rather
than just slow disease progression.
1.2. Real-world case reports suggested a role for vascular endothelial growth
factor inhibitors (anti-VEGF) in the treatment of neovascular AMD
In 1948, Michaelson described the process of neovascularisation in
the retina and hypothesised that a diﬀusible factor (“Factor X”) was
responsible for angiogenesis in hypoxic conditions (Michaelson, 1948).
Subsequent studies suggested that this Factor X was vascular en-
dothelial growth factor (VEGF) (Senger et al., 1983; Ferrara and Henzel,
1989; Aiello et al., 1994; Miller et al., 1997; Tolentino et al., 2002).
Animal studies demonstrated inhibition of tumour cell angiogenesis
could slow tumour growth (Holmgren et al., 1995; Parangi et al., 1996).
One of the ﬁrst anti-VEGF treatments to be developed was a humanised
monoclonal antibody eﬀective against isoform A of VEGF called bev-
acizumab (Avastin). After successful clinical trials demonstrated in-
creased median survival times with systemic bevacizumab combined
with chemotherapy versus chemotherapy alone, systemic bevacizumab
was approved for use in the treatment of colon cancer in 2004 (Hurwitz
et al., 2004).
Following the approval of a systemic anti-VEGF drug for the treat-
ment of colon cancer and the suspected role of VEGF in neovascular
AMD, clinicians used intravenous bevacizumab as an oﬀ-label treat-
ment for neovascular AMD. In a prospective case series (Michels et al.,
2005) of 18 patients treated with intravenous infusions of bevacizumab,
Michels et al. reported a median increase in visual acuity of 8 letters by
12 weeks. Rosenfeld et al. (2005) subsequently published the ﬁrst re-
port of intravitreal bevacizumab for a case of recurrent neovascular
AMD and reported visual beneﬁt. Intravitreal delivery had advantages
of lower drug dosage, a better systemic safety proﬁle, easier delivery
and lower cost. Retrospective case series provided further evidence that
intravitreal bevacizumab might improve visual acuity in neovascular
AMD (Spaide et al., 2006; Avery et al., 2006), highlighting the need for
robust randomised controlled trials.
1.3. Recording distance visual acuity
Changes in distance visual acuity have been used as the primary
endpoint in seminal clinical trials of anti-VEGF therapy for nAMD (see
Section 1.4).
The prototype distance visual acuity chart was developed in 1862
by Dutch ophthalmologist Hermann Snellen (Falkenstein et al., 2008).
“Standard vision” was deﬁned as the ability to recognise one of his
optotypes at a visual angle of 1min of arc. The original chart was later
modiﬁed to become what is now known as a Snellen chart. Although
widely used, this chart has a number of limitations, such as unequal and
unrelated spacing between letters and rows, inconsistent progression in
letter size from one line to the next, unequal legibility of letters used,
and large gaps between acuity levels at the lower end of the scale.
Bailey and Lovie (1976) introduced new principles for the design
and use of letter charts for the measurement of visual acuity. They
advocated that the test task should be essentially the same at each size
level on the chart. Such standardisation of the test task requires the use
of letters of equal legibility, the same number of letters on each row,
and uniform between-letter and between-row spacing. They also ad-
vocated that, combined with the test task standardisation, there should
be a logarithmic progression of letter size. These charts facilitate the use
of nonstandard testing distances which might be used when there is low
visual acuity or when examination room layout prevents testing at the
standard distance. This type of LogMAR chart was further modiﬁed by
Ferris et. al. in 1982 (Ferris et al., 1982) including use of the sans serif
font to improve legibility. This LogMAR chart was adopted for the Early
Treatment Diabetic Retinopathy Study (ETDRS chart) and later seminal
clinical trials. The ETDRS chart is a type of LogMAR chart. Therefore,
LogMAR letters can be considered equivalent to ETDRS letters. How-
ever, LogMAR letters is a more accurate term.
In a clinical trial setting refracted best-corrected distance VA readings
are obtained at important time-points with standard lumination and test
distances. In a real-world setting it may not be practical to carry out regular
refracted best-corrected distance VA measurements and lumination levels
and test distances may vary from visit to visit, potentially leading to less
accurate measurements. The International Consortium for Health
Outcomes Measurement Macular Degeneration Standard Set recommends
recording the best of uncorrected distance VA, corrected distance VA using
glasses or contact lenses, or pinhole if required in the aﬀected eye at each
clinical visit in the real-world setting (Rodrigues et al., 2016).
All visual acuity outcomes are reported in LogMAR letters in this
review. Table 1 provides a conversion table between Snellen distance
visual acuity and LogMAR distance visual acuity.
1.4. Seminal phase 3 clinical trials of intravitreal anti-VEGF therapy for
neovascular AMD
1.4.1. Pegaptanib
One of the initial intravitreal anti-VEGF treatments developed spe-
ciﬁcally for neovascular AMD was pegaptanib (Macugen), a single
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stranded nucleic acid aptamer that binds speciﬁcally to the 165 isoform
of VEGF hence antagonising its action. Subsequent trials demonstrated
that not only could pegaptanib reduce the rate of visual loss, it could
also lead to maintenance or improvement of vision in patients with
neovascular AMD compared to placebo (Gragoudas et al., 2004). Pe-
gaptanib was approved by the United States Food and Drug Adminis-
tration (FDA) in 2004 for treatment of neovascular AMD (F.D.A, 2005).
However, visual gains were not as impressive as later less speciﬁc anti-
VEGF agents and pegaptanib is no longer commonly used for subretinal
neovascularisation.
1.4.2. Ranibizumab
It was postulated that bevacizumab, which is a full length anti-VEGF
antibody, would be too large to suﬃciently diﬀuse through the retina to
reach the choroid. This led to the development of ranibizumab
(Lucentis) for intravitreal administration, which is essentially a Fab
fragment of bevacizumab with increased binding aﬃnity and inhibition
of the growth factor (Steinbrook, 2006). The Minimally classic/occult
trial of the Anti-VEGF antibody Ranibizumab in the treatment of Neo-
vascular Age-related macular degeneration (MARINA) and Anti-VEGF
antibody for the treatment of predominantly classic CHORoidal neo-
vascularisation in age-related macular degeneration (ANCHOR) were
two seminal randomised controlled trials that demonstrated the bene-
ﬁts of ranibizumab for neovascular AMD (Kaiser et al., 2007; Rosenfeld
et al., 2006; Brown et al., 2006).
The MARINA trial randomised patients to ranibizumab 0.3mg,
0.5mg and sham injections for a period of 24 months. After one year,
approximately 95% of the groups treated with ranibizumab lost fewer
than 15 letters from baseline compared with 62% receiving sham in-
jections. The ranibizumab 0.3mg and 0.5mg treatment groups were also
more likely to have at least a 15 letter VA gain (25% and 34% re-
spectively) compared with sham injections (5%). Quality of life im-
provements were also demonstrated with ranibizumab therapy (Kaiser
et al., 2007; Rosenfeld et al., 2006).
The ANCHOR trial randomised patients into treatment groups with
intravitreal ranibizumab (0.3mg or 0.5mg) and photodynamic therapy
with verteporﬁn (Brown et al., 2006). At one year groups treated with
ranibizumab lost fewer than 15 letters from baseline visual acuity in
94% and 96% of cases respectively compared with 64% receiving
verteporﬁn. Furthermore, ranibizumab-treated study eyes gained at
least 15 letters in 36% and 40% percent of cases respectively compared
with only 6% of study eyes that received photodynamic therapy. Ra-
nibizumab received FDA approval for the treatment of neovascular
AMD in 2006 (F.D.A, 2006).
The monthly intravitreal injections that were used in the pivotal
clinical trials pose a signiﬁcant treatment burden to patients, carers,
and healthcare providers. Therefore, discontinuous treatment regimens
(i.e. intravitreal injections less than every month) have been assessed in
clinical trial settings. In the phase 3b PIER clinical trial, eyes were
randomised to sham therapy or ranibizumab injections at ﬁxed 3
monthly intervals after an initial loading phase with 3 intravitreal in-
jections at 4 week intervals (Abraham et al., 2010; Regillo et al., 2008).
Mean visual gains at 3 months in the 0.3mg and 0.5mg ranibizumab
arms were +2.9 and + 4.3 letters respectively but these gains were not
maintained at 12 months (−1.6 and −0.2 letters) with this reduced
frequency ﬁxed treatment regimen.
Treatment regimens based on disease activity were explored. In the
Prospective OCT imaging of patients with Neovascular AMD Treated
with intraOcular ranibizumab (PrONTO) open-label single-arm study
(Lalwani et al., 2009), retreatment was given after 3 loading doses
every 4 weeks on an as required basis (pro re nata or “PRN”) based on
pre-deﬁned OCT and clinical criteria. Mean visual acuity improved over
2 years by 11.1 letters with an average of 9.9 injections, suggesting that
OCT-guided PRN treatment regimens could achieve similar visual out-
comes to monthly ranibizumab therapy with fewer intravitreal injec-
tions. However, the study was limited to 40 study eyes, had no control
arm and still required patients to be assessed every 4 weeks.
A prospective trial of the “treat-and-extend” regimen (which aims to
inject just before the lesion is about to reactivate) compared with
monthly dosing of intravitreal ranibizumab in treatment-naïve neo-
vascular AMD was conducted in 60 patients of whom 50 completed 24-
month follow-up at which point mean best-corrected LogMAR letter
gains were 10.5 for the monthly and 8.7 for the T&E cohorts (P= .64)
(Wykoﬀ et al., 2017) Over 24 months, the mean number of injections
administered was 25.5 and 18.6 for the monthly and T&E cohorts, re-
spectively (P < .001). The trial used an anatomic “no tolerance” ap-
proach where even very small amounts of ﬂuid, some at the limit of
detection, were treated as evidence of disease activity. Therefore, the
mean number of treatments administered to the T&E cohort over 24
months, 18.6, was more than that reported in management regimens
using monthly patient visits with PRN retreatment strategies, which
ranged from 12 to 14 injections (Martin et al., 2012). Interestingly, over
2 years of the CATT trial, nearly a third of PRN retreatments were
withheld from patients because of the presence of reading centre
identiﬁed ﬂuid on OCT not appreciated by trial investigators (Martin
et al., 2012). There is a question whether some degree of subretinal
ﬂuid can be tolerated (Razavi et al., 2015).
1.4.3. Bevacizumab
The ABC trial (Tufail et al., 2010) compared 1.25mg intravitreal
bevacizumab (three loading injections at six-week intervals followed by
further treatment if required at six-week intervals) with standard care
at the time (sham or pegaptanib for minimally classic or occult chor-
oidal neovascularisation and verteporﬁn photodynamic therapy for
predominantly classic choroidal neovascularisation) in 126 patients. At
the end of the 12-month study, the mean visual acuity gain was 7.0
letters in the bevacizumab group with a median of seven injections
compared with a loss of 9.4 letters in the standard care group
(P < .001).
Randomised controlled trials comparing intravitreal ranibizumab
and bevacizumab found similar eﬃcacy for the treatment of nAMD
(Chakravarthy et al., 2013; Martin et al., 2012). The Comparison of
AMD Treatment Trial (CATT) in the USA randomly assigned patients
with neovascular AMD into one of four treatment groups: intravitreal
Table 1
Conversion table between Snellen and LogMAR distance visual acuities.
Snellen (feet) Snellen
(metres)
LogMAR LogMAR letters (equivalent to
number of ETDRS letters read)
No Perception of Light 0
Perceives Light 1
Hand Movements 2
Count Fingers 3
20/800 6/240 1.6 4
20/630 6/190 1.5 5
20/500 6/150 1.4 10
20/400 6/120 1.3 20
20/320 6/95 1.2 25
20/250 6/75 1.1 30
20/200 6/60 1.0 35
20/160 6/48 0.9 40
20/125 6/38 0.8 45
20/100 6/30 0.7 50
20/80 6/24 0.6 55
20/63 6/19 0.5 60
20/50 6/15 0.4 65
20/40 6/12 0.3 70
20/32 6/9.5 0.2 75
20/25 6/7.5 0.1 80
20/20 6/6 0.0 85
20/16 6/4.8 −0.1 90
20/12.5 6/3.8 −0.2 95
20/10 6/3 −0.3 100
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bevacizumab (1.25 mg) or ranibizumab (0.5mg), either as regular
monthly injections or PRN (Brown et al., 2009; Martin et al., 2012). At
two-years, there was no signiﬁcant diﬀerence in the mean change in
visual acuity between the two drugs. Lower visual acuity gains were
observed in the PRN groups for both drugs compared with monthly
regimens. A similar multicentre randomised controlled trial in the UK
named Alternative treatments to inhibit VEGF in age-related choroidal
neovascularisation (IVAN) also concluded that ranibizumab and bev-
acizumab had similar eﬃcacy and that a reduction in the frequency of
retreatment using the PRN regimen resulted in a small loss of eﬃcacy
irrespective of the drug employed. The LUCAS multi-centre trial in
Norway compared ranibizumab and bevacizumab for neovascular AMD
according to a treat-and-extend protocol (Berg et al., 2015). Bev-
acizumab and ranibizumab had equivalent eﬀects on visual acuity at 1
year (7.9 and 8.2 mean letters gained respectively, P= .845) when
administered according to a treat-and-extend protocol (mean of 8.9 and
8.0 injections respectively). The visual acuity results at 1 year were
comparable to those of other clinical trials with monthly treatment.
The lower cost of oﬀ-label bevacizumab compared with licensed
intravitreal anti-VEGF agents has contributed to its widespread use.
However it is not formally licensed for this indication and care has to be
taken that the compounding pharmacies that prepare the intravitreal
bevacizumab from larger batches meet stringent quality controls to
reduce the risk of endophthalmitis (Goldberg et al., 2013).
1.4.4. Aﬂibercept
Aﬂibercept is a soluble fusion protein that, in addition to inhibiting
VEGF-A, also binds to VEGF-B (Holash et al., 2002), platelet-derived
growth factor and possibly Galectin-1 (Thijssen et al., 2006). The VIEW
1 and 2 phase 3 clinical trials (Heier et al., 2012; Schmidt-Erfurth et al.,
2014) enrolled 2457 study eyes. From baseline to week 52, patients
received either aﬂibercept 0.5mg every 4 weeks (0.5Q4), aﬂibercept
2mg every 4 weeks (2Q4), aﬂibercept every 8 weeks after three
monthly loading injections (2Q8), or 0.5mg intravitreal ranibizumab
every 4 weeks (RQ4). The three ﬁxed interval aﬂibercept groups had
similar VA gains compared with ﬁxed interval ranibizumab at 52
weeks, with mean BCVA gains ranging from 8.3 to 9.3 letters. In the
second year of the trial a PRN approach was followed in all treatment
arms with the maximum treatment interval capped at 12 weeks. The
visual acuity gains at 52 weeks in all treatment arms were not fully
maintained at week 96 with the mean BCVA gain ranging from 6.6 to
7.9 letters, with the most likely cause being the reduced frequency of
intravitreal injections in year 2. Patients received on average 16.5,
16.0, 16.2, and 11.2 injections over 96 weeks and 4.7, 4.1, 4.6, and 4.2
injections during weeks 52 through 96 in the Rq4, 2q4, 0.5q4, and 2q8
groups, respectively. The 2q8 aﬂibercept group had similar mean visual
acuity outcomes to the q4 aﬂibercept and q4 ranibizumab groups over
96 weeks, but with an average of 5 fewer injections. There was no 2q8
ranibizumab arm in this trial. The incidence of Antiplatelet Trialists'
Collaboration-deﬁned arterial thromboembolic events from baseline to
week 96 were similar amongst the aﬂibercept and ranibizumab groups
(2.4%–3.8%). Aﬂibercept was approved by the FDA in November 2011
(F.D.A, 2011).
1.5. The need for real-world evidence in neovascular AMD
It may be contended that the seminal phase 3 randomised controlled
trials reporting the outcomes of anti-VEGF therapy for neovascular
AMD had good internal validity at the expense of lower external va-
lidity. The stringent inclusion and exclusion criteria, relatively small
patient numbers, intensive treatment regimens and limited duration of
these clinical trials may not necessarily reﬂect real-world experience.
Real-world data was deﬁned by the European Medicine Agency in 2016
as “data collected outside randomised clinical trials usually during
normal clinical care” (E.M.A, 2016). The FDA deﬁned real-world evi-
dence as the “evidence derived from aggregation and analysis of real-
world data elements” (F.D.A, 2016). Table 2 highlights that although
real-world studies (e.g. from registries) represent a lower level of cer-
tainty on the evidence hierarchy, they can complement ﬁndings from
randomised controlled trials and have higher external validity since
they reﬂect everyday clinical practice (Black, 1996).
Large-scale population-based observational studies have already
shown their value in identifying signiﬁcant drug adverse events of
drugs that were not detected in clinical trials. Real-world evidence has
led to subsequent withdrawal of drugs that initially appeared promising
in phase 3 clinical trials, such as the lipid lowering medication cer-
ivastatin (Furberg and Pitt, 2001). Post-marketing observational stu-
dies, which are carried out after regulatory approval has been given,
ensure earlier clinical trials results extend to the general population
receiving the new medication. These real-world studies may determine
small but signiﬁcant treatment eﬀects in routine clinical practice by
tracking patients for longer and assessing a broader set of endpoints,
including safety, quality of life, and long-term eﬀectiveness.
2. Development of global registries to record real-world outcomes
in neovascular AMD
2.1. Fight Retinal Blindness registry!
The Fight Retinal Blindness! (FRB!) registry has been tracking out-
comes of anti-VEGF treatment for nAMD in Australia, New Zealand and
Switzerland since 2007 (Gillies et al., 2014). In order to facilitate ac-
curate, systematic and standardised observation of data across various
centres, a practical, web-based tool was developed for data entry. The
aim of this interface was to enable monitoring and assessment of dif-
ferent treatment regimens on a large scale while keeping the workload
for clinicians at a minimum. Data entry takes approximately 30 s for a
new patient and 15 s for a follow-up consultation and is completed
during routine clinics. Registered clinicians can input data relating to
treatments for patients with neovascular AMD and other retinal dis-
eases to create a user-friendly screenshot of the patient's treatment
history. These analytics can be utilised for self-audit and there is the
option to pool anonymised data with other departments nationally and
internationally using the application.
Publications from FRB! investigators have addressed many clinically
relevant issues of treating neovascular AMD in the “real-world”, in-
cluding optimum treatment regimens (Arnold et al., 2015; Barthelmes
et al., 2018; Essex et al., 2016), time to inactivation of choroidal neo-
vascular lesions (Gillies et al., 2015b), the results of switching anti-
VEGF therapy (Barthelmes et al., 2016), and long-term outcomes with
anti-VEGF therapy (Gillies et al., 2015a). As of February 2017, the FRB!
registry included data from approximately 118,000 treatments from
about 8000 eyes of 7000 patients with neovascular AMD. Around 3000
patients are currently actively tracked. A number of global sites in UK,
Europe, Middle-East and Asia have commenced tracking their real-
world outcomes of anti-VEGF therapy for neovascular AMD using this
Table 2
Strengths and weaknesses of randomised controlled trials and real-world registries.
Randomised controlled trial Real-world study
Randomisation Yes No
Control arm Yes Not necessarily
Sample size Smaller Larger
Internal validity Higher Lower
External validity Lower Higher
Exclusion criteria Multiple None or few
Patient comorbidities Fewer More
Treatment regimen Fixed and protocol driven Variable
Outcomes assessed Narrow Can be broader
Cost More expensive Less expensive
Duration Shorter Longer
Patient retention Greater Less
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software platform, oﬀering exciting opportunities for global compar-
isons of outcomes in the future (Ozturk et al., 2017). Further analyses
from FRB! investigators are included in the following sections.
2.2. UK AMD EMR dataset
Medisoft was founded in 1997 by the late Robert Johnston, a
Consultant Ophthalmologist and his brother David Johnston, who
brought commercial and marketing experience from the pharmaceu-
tical industry. This software evolved over time and uptake increased in
the UK, with over 20 ophthalmology departments in England and
Northern Ireland contributing real-world data on outcomes of in-
travitreal anti-VEGF therapy for neovascular AMD. Further collabora-
tions have been developed between University College London Farr
Institute of Health Informatics Research and UK ophthalmology de-
partments to extract pseudoanonymised clinical data (> 3.5 million
clinic visits), and imaging data (40 + million OCT slices). This has
allowed benchmarking of real-world outcomes to set national standards
(Liew et al., 2016), development of novel heath economic models to
guide cost-eﬀectiveness of drugs (Butt et al., 2017), and provided evi-
dence to support funding of treatments currently rationed by the UK
National Institute of Clinical Excellence (Lee et al., 2015, 2017b).
Further analyses from the UK AMD EMR users group are also included
in the following sections.
2.3. European registries
A total of 3470 patients from 274 centres in Germany received in-
travitreal ranibizumab for neovascular AMD in the observational WAVE
study. The initial German guidelines recommended a loading phase of
three intravitreal injections at 1-month intervals, followed by a main-
tenance phase where patients received retreatment if signs of activity
were noted. Patients received a mean of 4.34 (SE= 0.05;
median=3.0) ranibizumab injections over 12 months, with negligible
change in mean visual acuity from baseline to month 12 (Watson et al.,
2017). Following these results, German authorities changed re-
imbursement and re-injection policy to promote better outcomes.
In the real-life LUMIERE observational study set in France up to
2009, 551 patients received an average of 5.1 intravitreal ranibizumab
injections for neovascular AMD with a mean change in VA from base-
line to month 12 of +3.2 letters (Cohen et al., 2013). The TWIN Study
reviewed clinical outcomes in France between 2010 and 2011 (Souied
et al., 2015) in 881 patients, identifying a mean gain in visual acuity of
+4.3 letters over 12 months. Signiﬁcant improvements were docu-
mented in the mean interval between diagnosis and treatment initiation
in the TWIN study compared with the LUMIERE study (down from 12.6
to 7.7 days; P < .001). After induction, hardly any patients were
monitored every month in the TWIN study as recommended, although
retreatment was more frequent than in the earlier LUMIERE study
(mean 5.6 versus 5.1 injections; P < .001).
The Swedish Macula Register (SMR) was established in 2003, went
online in 2008 and now covers approximately 82% of all patients with
neovascular AMD in Sweden (Westborg et al., 2014). In December
2013, the SMR included nearly 15300 patients and 105300 intravitreal
treatments. The data in the SMR are from specialised outpatient retinal
clinics. The number of intravitreal anti-VEGF injections was reported to
be an important factor for treatment outcomes after 1 and 2 years of
therapy (Westborg et al., 2017).
The AURA study was funded by Bayer HealthCare Pharmaceuticals
AG, Leverkusen, Germany. It was a retrospective, observational, mul-
ticentre study of 2227 patients conducted in France, Germany, Italy,
Netherlands, UK, Ireland, Canada and Venezuela (Holz et al., 2016). Of
the eight countries, ﬁve enrolled more than 400 patients (France,
Germany, UK, Italy and the Netherlands), hence this is a predominantly
European dataset. Mean change in visual acuity score from baseline to
years 1 and 2 was +2.4 and + 0.6 letters, respectively. Patients
received a mean of 5.0 and 2.2 injections in the ﬁrst and second year,
respectively. There were substantial diﬀerences in visual outcomes and
injection frequency between countries. More frequent injections and
worse baseline vision were associated with greater improvements in
visual acuity. The diﬀerences in visual outcomes between countries is
likely due to varying constraints within their healthcare systems, in-
cluding reimbursement, selection of patients for treatment, time until
treatment is initiated and the number of injections permitted.
2.4. Development of registries in the USA (IRIS)
The American Academy of Ophthalmology Intelligent Research in
Sight (IRIS) registry launched in 2014 has already become the largest
American clinical specialty data registry with nearly 50 million patient
visits and over 14 million patients (De Fauw et al., 2017). This is in
comparison to a prior attempt at a clinical outcomes registry, the Na-
tional Eye Care Outcomes Network (NEON) launched in 1995, which
accumulated only 17,876 patients from 249 participating ophthalmol-
ogists over 5 years of operation before its decline (Lum et al., 2002).
The key lessons learned from the NEON database were that manual
double data entry by practices was untenable and, for the eﬀort to be
sustained, data collection had to be a seamless component of workﬂow.
Therefore, the IRIS registry is designed to extract data from the prac-
tice's server which contains the electronic medical record (EMR) data-
base using systems integrator software, creating a large central re-
pository of structured data from across diverse EMR systems. Data from
the IRIS registry has already been used to characterise treatment pat-
terns of myopic choroidal neovascularisation in the USA (Willis et al.,
2017). As of 1st July 2017, 16,737 physicians from 5097 practices are
participating in the IRIS registry, contributing over 147 million visits
from over 37 million patients. Approximately 6 million anti-VEGF in-
jection episodes have so far been recorded in the IRIS registry (Personal
communication, Flora Lum, 5th September 2017). The IRIS registry
should provide useful insights in to outcomes of neovascular AMD
treated with anti-VEGF agents.
2.5. The LUMINOUS study
LUMINOUS (NCT01318941), a recently-completed, ﬁve-year, multi-
centre, global, observational study, was designed to evaluate the long-
term eﬀectiveness, safety, and treatment patterns associated with in-
travitreal 0.5 mg ranibizumab in clinical practice across all licensed
indications (nAMD, diabetic macular oedema, branch and central ret-
inal vein occlusion, and myopic choroidal neovascularisation). This
study was initiated in March 2011 and recruited a total of 30,138 pa-
tients from 488 sites across 42 countries, of whom 22,717 had nAMD.
A total of 6241 patients with nAMD were treatment-naïve and at
baseline the mean age of this cohort was 75.0 years, 54.9% were fe-
male, 66.5% were Caucasian and 29.3% were Asian. Of these patients,
2665 (42.7%) had pigment epithelium detachment, 572 (9.2%) had
polypoidal choroidal vasculopathy and 246 (3.9%) had retinal angio-
matous proliferation (Brand et al., 2017).
There was 12 month visual acuity data available for a total of 3379
treatment-naïve nAMD eyes. The mean baseline VA was 51.9 letters
with a mean VA of 55.0 letters at month 12, corresponding to a gain of
+3.1 letters (Holz et al., 2017). This improvement in VA was achieved
with a mean number of 5.0 ranibizumab injections, which was mark-
edly less than the number administered in pivotal clinical trials, such as
ANCHOR (Brown et al., 2006) and MARINA (Rosenfeld et al., 2006). In
addition, no new safety signals for ranibizumab were observed during
the LUMINOUS study (Holz et al., 2017), despite enrolling patients with
more diverse co-morbidities than those generally encountered in ran-
domised controlled trials.
Increased injection frequency was associated with higher 12 month
VA gains. Treatment-naïve nAMD eyes receiving ≤3 (n = 537), 3–6
(n = 1924), and> 6 injections (n = 918) had mean VA gains of +1.6,
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+3.3, and +3.7 letters, respectively. Notably, patients receiving ≥10
injections (n = 224, a subset of those patients receiving>6 injections)
had mean VA improvements of +5.7 letters (Holz et al., 2017). Fur-
thermore, month 12 VA changes in these patients stratiﬁed by baseline
VA of< 23 (n = 382), 23–<39 (n = 559), 39–<60 (n = 929),
60–<74 (n = 994) and ≥74 letters (n = 515) were +12.6, +6.7,
+3.6, +0.3 and −3.0 letters respectively (Fig. 1) (Holz et al., 2017),
indicating that baseline VA should be considered when interpreting
visual outcomes.
Ongoing analyses on country level data and patients who were not
treatment-naïve upon recruitment to the study are continuing.
However, other real-world registries may oﬀer more rapid and com-
prehensive data collection for some of these outcomes at considerably
lower cost.
3. Benchmarking real-world outcomes
3.1. Patient demographics and baseline characteristics
It is important that patient demographics and baseline character-
istics are recorded to allow meaningful comparison of outcomes
(Rodrigues et al., 2016).
The mean age of patients in seminal clinical trials is on average
slightly lower than real-world practice. In a meta-analysis of real-world
studies that included over 24000 patients receiving intravitreal rani-
bizumab for neovascular AMD, the mean age of patients was 78.8 years
(95% conﬁdence interval [CI]: 78.0–79.5 years) (Kim et al., 2016)
compared with 77 and 76 years respectively in the MARINA and AN-
CHOR clinical trials of 0.5mg ranibizumab (Brown et al., 2006;
Rosenfeld et al., 2006). The average age of patients at entry Into the
VIEW 1 and 2 aﬂibercept registration clinical trials was 78 and 74 years
respectively (Heier et al., 2012). Younger patients are likely to have less
comorbidities.
Gender has not been noted to aﬀect visual outcomes. In the VIEW 1
and 2 clinical trials the proportion of females in the diﬀerent treatment
groups ranged between 50% and 64% without aﬀecting visual out-
comes (Heier et al., 2012). A meta-analysis of 42 real-world studies of
intravitreal ranibizumab for neovascular AMD found that 63% of pa-
tients were female (Kim et al., 2016). Similarly, in a real-world study of
intravitreal ranibizumab for neovascular AMD in a well-deﬁned region
of rural England, 65% of patients were female (Keenan et al., 2013).
There is evidence for greater risk of neovascular AMD in females
compared with males even taking into account greater longevity in
females (Rudnicka et al., 2012).
Lesion type as deﬁned by fundus ﬂuorescein angiography may aﬀect
treatment outcomes. Minimally classic and occult lesions, which are
mainly sub-RPE (type 1 lesions) were included in MARINA, which was
sham-controlled. Predominantly classic lesions, which are mainly sub-
retinal (type 2 lesions) and responded to photodynamic therapy with
verteporﬁn, were included in ANCHOR (Brown et al., 2006; Rosenfeld
et al., 2006). These lesion subtypes were well matched across the dif-
ferent treatment groups of the VIEW 1 and 2 clinical trials (occult
36%–41%, minimally classic 32%–37%, predominantly classic
23%–29%) (Heier et al., 2012). In a real-world study of intravitreal
ranibizumab for neovascular AMD in a well-deﬁned region of rural
England with a predominantly White population, the proportion of
patients with an occult lesion was 51% and lesions with any classic
component constituted 36% of all lesions (Keenan et al., 2013). Of the
9350 eyes with data available on their CNV lesion in a global meta-
analysis, the majority had an occult lesion (50%), followed by lesions
with a classic component (29%) and 18% of lesions unclassiﬁed (Kim
et al., 2016). The FRB! investigators identiﬁed that occult lesions be-
came inactive more slowly than classic lesions without an apparent
eﬀect on visual acuity outcomes (Barthelmes et al., 2015; Gillies et al.,
2015b). In the above real-world studies, patients from Asia were un-
derrepresented, where there are higher rates of idiopathic polypoidal
choroidal vasculopathy reported (Wong et al., 2016).
3.2. Visual acuity outcomes
3.2.1. Baseline visual acuity
Five year real-world outcomes of intravitreal ranibizumab for neo-
vascular AMD in 549 eyes from the FRB! registry mainly set in
Australia, stratiﬁed by baseline VA are illustrated in Fig. 2 (Gillies et al.,
2015a). Eyes with better baseline VA maintain good vision for longer
although there is less scope for improvement in VA because of a ceiling
eﬀect.
Therefore, baseline VA must be considered when interpreting visual
acuity gains over time. The mean baseline VA when intravitreal anti-
VEGF therapy is started reﬂects how well patients can access a service,
whereas the visual acuity change over time stratiﬁed by baseline VA
reﬂects the quality of the injection service. The FRB! investigators as-
sessed diﬀerences in visual outcomes for neovascular AMD treated with
intravitreal anti-VEGF between two states in Australia, New South
Wales (NSW) and Victoria (VIC) (Gillies et al., 2015). In total, 808 eyes
were studied (NSW 540, VIC 227). Mean baseline VA (NSW 60.7, VIC
54.8 LogMAR letters) and mean 24 month VA (NSW 66.3, VIC 62.2
LogMAR letters) for the two states were signiﬁcantly diﬀerent
(P < .001). Eyes received a similar number of injections over 24
months (NSW 12.4, VIC 12.2) with similar injection intervals (NSW
54.9 days, VIC 53.0 days). If the quality of service was simply deﬁned as
mean VA gain, then VIC could incorrectly be perceived to have better
outcomes. However, the issue appeared to be delay in accessing treat-
ment in some centres in Victoria leading to worse baseline VA. Com-
paring real-world outcomes allows issues to be highlighted and inter-
ventions introduced to improve patient outcomes.
Fig. 1. Visual acuity (VA) outcomes in LogMAR
letters at month 12 stratiﬁed by baseline VA in
treatment-naïve nAMD eyes from the LUMINOUS
Study. Reproduced with permission from Wayne
Macfadden, Novartis Pharma AG, Basel,
Switzerland. n= number of patients with evalu-
able data at baseline and month 12.
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The UK AMD EMR Users group assessed inter-centre variation in VA
outcomes with the aim of establishing real-world standards of care
(Liew et al., 2016). A prospective multicentre national database study
of 13 UK centres that treated patients according to a set protocol (three
monthly loading doses followed by PRN retreatment) was performed. A
total of 5811 treatment-naive eyes of 5205 patients were assessed.
There was considerable variation in mean baseline VA between centres
ranging from 48.9 to 59.9 LogMAR letters. The reasons for this disparity
between services warrant further investigation to improve patient
outcomes.
3.2.2. Short-term visual outcomes
A meta-analysis of real-world studies of intravitreal ranibizumab for
neovascular AMD identiﬁed 42 global studies including over 24000
eyes with at least one year follow-up on the search date of 1 May 2015
(Kim et al., 2016). Overall, there was a weighted mean change of +5.0
(95% CI: 3.4 to 6.6), +3.4 (95% CI: 0.9 to 5.8), and +1.1 (95% CI: 25.3
to 7.5) LogMAR letters at 1 year (n = 24,039), 2 years (n = 17,928),
and ≥3 years (n = 13,012), respectively. Most patients had a baseline
VA between 35 and 55 LogMAR letters (n = 17,464; 6/60 to 6/24
Snellen equivalent). This was followed by the 55 to 70 LogMAR letters
group (n = 4675; 6/24 to 6/12 Snellen equivalent) and those with
VA>70 ETDRS letters (n = 1729;> 6/12 Snellen equivalent). Pa-
tients who commenced treatment with better baseline VA maintained
better VA up to at least 36 months. The mean change in VA in the ﬁrst
year of treatment generally increased with the mean number of injec-
tions that were administered. The visual outcomes stratiﬁed according
to treatment regimen are summarised in Table 2 in Section 3.3.
The UK AMD EMR Users group assessed 92,976 ranibizumab in-
jections for 12,951 eyes of 11,135 patients (Tufail et al., 2014). For eyes
followed up for at least 3 years, mean VA at baseline was 55 LogMAR
letters, at 1 year 57 (+2) letters, at 2 years 56 (+1) letters, and at 3
years 53 (−2) letters using a predominantly prn retreatment approach.
The median number of treatments for eyes followed up for at least 3
years in years 1, 2 and 3 was 5, 4, and 4, respectively, and the median
number of outpatient visits was 9.2, 8.2, and 8.2, respectively. Baseline
VA was related inversely to mean vision gain at 3 months.
The FRB! investigators reported outcomes of intravitreal anti-VEGF
therapy, predominantly with ranibizumab, for treatment-naive eyes
with neovascular AMD using a treat-and-extend treatment regimen in
routine clinical practice. Data from 1198 eyes from 1011 patients with
24-month follow-up between 2007 and 2012 were included in the
analysis. The mean VA increased by +5.3 LogMAR letters from 56.5
letters at baseline to 61.8 letters at 24 months. Mean VA gains improved
and number of injections increased with successive years from +2.7
letters for eyes commencing in 2007 after a mean of 9.7 injections in 2
years, to +7.8 letters for eyes commencing in 2012 after a mean of 14.2
injections over 2 years. The proportion of eyes with VA>6/12 in-
creased from 27% at baseline to 45% after 24 months; the proportion
with vision of< 6/60 remained unchanged (13% at baseline and 11%
at 24 months). Of the included eyes, 90.5% avoided a vision loss of
≥15 letters. There was an overall mean of 13.0 injections over the 24
months, 7.5 injections in the ﬁrst year and 5.5 in the second year, with
a mean of 14.8 clinic visits. These data indicate that eyes managed in
routine clinical practice with a treat-and-extend regimen could achieve
good visual outcomes while decreasing the burden of treatments and
clinic visits (Arnold et al., 2015).
Visual outcomes in treatment-naïve eyes receiving ﬁxed interval
intravitreal aﬂibercept according to the VIEW protocols over 1 year was
assessed in routine clinical practice in 16 UK centres (Talks et al.,
2016). The mean age at presentation was 80.0 years (median, 81.0
years) and 63.7% were female. During the ﬁrst year of treatment with
aﬂibercept, 1840 treatment-naive eyes of 1682 patients received a
median of 8 (mean, 7.0) injections at a median of 8 (mean, 7.3) visits.
The mean baseline VA was 53.7 LogMAR letters improving to 58.8
letters (+5.1 letter gain) at 1 year. The proportion achieving ≥70
letters increased from 16.4% at baseline to 33.7% at 1 year, and 92%
avoided moderate visual loss at 1 year. The mean visual acuity gain
+5.1 letters at 1 year was comparable to +8.4 letters in the integrated
analysis of the VIEW 1 and VIEW 2 studies (Heier et al., 2012). With
adequate treatment frequency, real-world outcomes can be comparable
with clinical trial outcomes.
A real-world study has reported that the visual beneﬁts achieved
with aﬂibercept in the ﬁrst year can be maintained in the second year
with a treat-and-extend regimen (Eleftheriadou et al., 2017). The ﬁxed
dosing protocol of the VIEW study was largely followed in year 1 and
then a protocol used by Moorﬁelds Eye Hospital (London) re-
commended using a treat-and-extend approach in year 2 with a max-
imum extension of treatment interval of 3 months. Retrospective ana-
lysis of 109 consecutive treatment naive eyes from 102 patients were
assessed with data from 94 eyes of 88 (86%) patients available at 2
years. Over the 2 years, these eyes received a median of 12 (mean, 11.4;
SD, 4) injections, with mean VA improving from 55.9 (SD, 15) letters at
baseline to 61.3 (SD, 16.9) letters (mean VA gain 5.4 letters) at 1 year
and to 61.0 (SD, 17.1) letters (mean VA gain 5.1; SD, 14.9 letters) at 2
years. The results suggest that good outcomes can be achieved in the
real-world using aﬂibercept for neovascular AMD with treat-and-extend
posology in the second year of treatment after following the VIEW
protocol in the ﬁrst year.
Can a treat-and-extend approach from baseline yield better results?
The FRB! investigators reported 24-month outcomes using aﬂibercept
in 136 eyes of 123 patients for neovascular AMD using a treat-and-
extend regimen (Barthelmes et al., 2018). Mean (SD) age was 77.2 (7.0)
years, 59% were female. Mean (SD) VA increased from 61.4 (17.4)
Fig. 2. Reproduced from Long-term out-
comes of treatment of neovascular AMD:
Data from an observational study (Gillies
et al., 2015a). Loess regression curves of
visual acuity over 5 years of intravitreal
anti-VEGF therapy stratiﬁed by baseline vi-
sual acuity.
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letters at baseline to 67.4 (17.7) letters at 24 months (+6.0 letters
[95% CI: 3.3–8.5]; P < .001). From baseline to 24 months, the pro-
portion of eyes with visual acuity ≥70 letters (6/12) increased
(40%–58%, P < .001) and the proportion of eyes with visual acuity
≤35 letters (6/60) remained the same (10%; P = .547). Ninety-eight
per cent of eyes starting with visual acuity ≥70 letters were able to
maintain this up to 24 months. From the ﬁrst to the second year of
treatment, the mean [SD] number of injections (7.8 [2.1] versus 5.7
[2.6]; P < .001) and visits (8.7 [1.7] versus 6.5 [2.4]; P < .001)
decreased for eyes completing 24 months of treatment. Fig. 3 demon-
strates that although the mean number of aﬂibercept injections re-
quired over year 1 was similar between the treat-and-extend regimen
and the VIEW protocol ﬁxed interval regimen, there can be consider-
able variation when dealing with individual eyes with some requiring
more and some less treatment. When data from 60 eligible eyes that did
not complete 2 years follow-up, along with 14 eyes that switched to
ranibizumab, were included using last observation carried forward, the
mean change in VA from baseline was +5.6 letters (95% CI: 3.3–7.7).
Comparisons between observational datasets must be done with
care. In this case, a good gain of around 5 letters after 12 months of
treatment with aﬂibercept was reported by Talks et al. using the VIEW
proticol in the ﬁrst year. Eleftheriadou et al. conﬁrmed this in another
UK population and reported that the mean gain held at 2 years using a
treat-and-extend regimen. The FRB! investigators reported a similar
mean VA improvement with a treat-and-extend regimen from the start,
however the mean pre-treatment VA in their cohort was at least 5 let-
ters greater than the other studies, resulting in better overall outcomes.
These better outcomes are at least as likely to be due to earlier inter-
vention in the FRB! cohort as to a superiority of a treat-and-extend
regimen over ﬁxed interval dosing in the ﬁrst year of treatment.
3.2.3. Long-term visual outcomes
Real-world data collection allows long-term results to be obtained
that might not be practical with randomised controlled trials. The FRB!
investigators analysed the long-term outcomes of treatment-naive eyes
with neovascular AMD that had started treatment with intravitreal anti-
VEGF therapy (predominantly ranibizumab) at least 5 years previously.
Locally weighted scatterplot smoothing curves (Loess regression curves)
were used to display VA results (Fig. 4). The mean follow-up time of all
1212 identiﬁed eyes was 53.5 months and 549 (45%) continued at-
tending after 60 months. Mean VA improved from 55.1 to 61.4 letters
after 6 months and remained above the mean presenting VA for ap-
proximately 5 years. After 7 years, mean VA was 2.6 letters lower than
baseline for the 131 eyes still being followed; 40% had VA≥ 70 (6/12)
letters and 18% had VA≤ 35 letters (6/60). Of those with 6/12 VA
before treatment, 60% maintained it after 7 years. The cause of loss
≥10-letters in a subset of eyes were retrospectively analysed: 37% of
these were said by the investigators to be due to geographic atrophy
aﬀecting the centre of the fovea. A median of 6 injections and 9 visits
were recorded over the ﬁrst 12 months, and then 5 treatments and 7 to
9 visits per annum thereafter through 7 years.
The FRB! results were better than the report from the SEVEN-UP
extension study of patients who had participated in ANCHOR or
MARINA then HORIZON clinical trials and were subsequently treated in
routine clinical practice. These patients had a mean loss of 8.6 letters
over 7 years. The main diﬀerence between the studies was that patients
in the FRB! registry received substantially more injections from the
third year (Gillies et al., 2015a; Rofagha et al., 2013). Similarly, The
Fig. 3. Percentage of eyes and their mean treatment interval during various periods since
beginning aﬂibercept monotherapy for those eyes which completed 2-year follow-up.
Reproduced from Two year outcomes of "treat-and-extend" intravitreal therapy using
aﬂibercept preferentially for neovascular AMD (Barthelmes et al., 2018).
Fig. 4. Reproduced from Long-term out-
comes of treatment of neovascular AMD:
Data from an observational study (Gillies
et al., 2015a). Loess regression curve of
mean visual acuity (VA) in LogMAR letters
for all 1212 eligible eyes over time. At each
time-point, the number of eyes still being
followed is displayed above the horizontal
axis. The red solid line represents the Loess
curve for the VA, and the black dashed line
represents the mean baseline VA for those
eyes still observed at the marked time-
points.
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CATT long-term study highlighted an average of 3.3 letters lost 5 years
after starting treatment compared with 0.7 letters lost in the FRB!
registry (Comparison of Age-related Macular Degeneration Treatments
Trials Research et al., 2016; Gillies et al., 2017). These ﬁndings suggest
that visual acuity at baseline together with treatment regimen and in-
tensity are the most signiﬁcant inﬂuences on long-term visual out-
comes.
Aﬂibercept entered the market later than ranibizumab and therefore
less long-term real-world data is available currently but would be ex-
pected in the future.
3.2.4. Incidence of sight impairment and blindness
The incidence of sight impairment and blindness in 11,135 treat-
ment-naive patients receiving ranibizumab for neovascular AMD in the
UK over 4 years was studied by the UK AMD EMR Users group
(Johnston et al., 2016). The cumulative incidence of new sight im-
pairment (VA in better-seeing eye worse than 6/15) and blindness (VA
in better seeing-eye worse than 6/60) in patients with treated neovas-
cular AMD in at least 1 eye at years 1–4 after the ﬁrst injection were
29.6%, 41.0%, 48.7%, and 53.7% for new sight impairment and 5.1%,
8.6%, 12% and 15.6% for new blindness, but with signiﬁcantly lower
rates for patients that started treatment later (P < .0001). One reason
for the decreasing incidence of sight impairment and blindness in later
cohorts was that baseline VA of the worse-seeing eye improved over
time as the legacy of absence of anti-VEGF treatment decreased over
time. An important limitation of the study was the unknown status of
the patients who were censored due to loss of follow-up (see Section
5.2).
From 2000 to 2010 the incidence of legal blindness in Denmark
from both neovascular and geographic AMD fell to half the baseline
incidence. The bulk of the reduction occurred after the introduction of
intravitreal anti-VEGF agents in 2006 (Bloch et al., 2012). Similarly,
following the introduction of intravitreal ranibizumab in south-east
Scotland, there were annual decreases in the incidence of blindness
attributable to neovascular AMD (Borooah et al., 2015). Cases in the
south-east Scotland population fell from a peak of 9.1 cases per 100000
in 2006 to a trough of 4.8 cases per 100000 in 2011, a decline of 47%
from the peak level.
Whilst eﬀective treatments to reduce the incidence blindness are
welcome, it has been suggested that on a population level the beneﬁcial
eﬀects of the new treatments for neovascular AMD will be outweighed
by the large number of new cases due to the strong anticipated 'ageing'
eﬀect in countries such as the UK (Minassian et al., 2011).
3.3. Comparing real-world outcomes with diﬀerent treatment regimens
The continuous monthly dosing of intravitreal anti-VEGF therapy
that was proposed for ranibizumab on the basis of the MARINA and
ANCHOR studies proved to be impractical in a real-world setting. As a
result, three broad strategies have gained popularity in real-world
practice: PRN, treat-and-extend and ﬁxed interval dosing (see Section
1.3). There is the opportunity to compare visual outcomes from ob-
servational studies with these diﬀerent treatment strategies provided
baseline characteristics are well matched.
PRN re-treatment approaches were popular in many countries, in-
cluding the UK. The UK AMD EMR Users group assessed inter-centre
variation in VA outcomes with the aim of establishing real-world
standards of care for three monthly loading doses followed by PRN
retreatment (Liew et al., 2016). A total of 5811 treatment-naive eyes of
5205 patients received a total of 36 206 ranibizumab injections over 12
months. The mean baseline VA between centres varied from 48.9 to
59.9 LogMAR letters. Mean inter-centre VA change from baseline to 12
months varied from+6.9 letters to−0.6 letters (mean of +2.5 letters).
The proportion of eyes achieving VA of 70 letters or more varied be-
tween 21.9% and 48.7% at 12 months. The median number of injec-
tions (visits) at each centre varied from 5 to 8 (9–12), with an overall
median of 6 (11). Age, baseline VA, number of injections and number of
visits but not gender were associated with variation in these VA out-
comes (P < .01).
A meta-analysis of global real-world outcomes of over 24000 eyes
treated with ranibizumab for neovascular AMD suggested that treat-
and-extend regimens were associated with better visual outcomes than
PRN regimens, although more injections were required to achieve this
(Table 3). Both groups had similar mean baseline visual acuity but there
may have been diﬀerences in baseline characteristics (Kim et al., 2016).
A similar observation was made comparing PRN treatment in 5 UK
centres with a treat-and-extend approach in 4 Australian centres. The
study included patients with a diagnosis of neovascular AMD who
started treatment with ranibizumab between 2009 and 2014. A total of
647 eyes of 570 patients in Australia and 3187 eyes of 2755 patients in
the UK with complete 12-months follow-up were analysed. Baseline
patient characteristics were comparable between the two cohorts. After
1 year of treatment, treat-and-extend treated eyes achieved higher
mean VA gains (5.0 [95% CI: 3.9–6.1]) than PRN treated eyes (3.0
[95% CI: 2.6–3.5] LogMAR letters); diﬀerence in means 2.1 (95% CI:
0.7–3.4), P < .001]. Over the 12-month follow-up, treat-and-extend
treated eyes received a higher mean (+/-SD) number of injections
(9.3 ± 2.4) than PRN treated eyes (6.0 ± 2.2) (P < .0001). The
treat-and-extend cohort had a lower mean (+/-SD) number of clinic
visits (10.29 ± 2.90) than the PRN cohort (11.47 ± 2.93)
(p < .0001). The higher injection frequency in the treat-and-extend
cohort likely accounts for the trend towards improved visual outcomes
(Johnston et al., 2017).
The UK AMD EMR Users group compared the eﬀectiveness of ﬁxed
interval or treat-and-extend aﬂibercept versus PRN ranibizumab
therapy for neovascular AMD (Lee et al., 2017a). They assessed 1-year
outcomes in 1884 eyes (942 in each cohort) with groups matched for
age, gender, baseline VA and year of starting treatment. At year 1,
patients on PRN ranibizumab gained 1.6 LogMAR letters (95% CI: 0.5
to 2.7), while patients on ﬁxed interval or treat-and-extend aﬂibercept
gained 6.1 letters (95% CI: 5.1 to 7.1). The ﬁxed interval or treat-and-
extend aﬂibercept group had signiﬁcantly more injections compared
Table 3
Modiﬁed from Table 4 in Meta-analysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration (Kim et al., 2016). VA =
Visual acuity. ΔVA = Change in visual acuity. CI = Conﬁdence Interval.
Treatment Regimen Baseline VA
(95% CI)
ΔVA at 1 year
(95% CI)
ΔVA at 2 year
(95% CI)
ΔVA at 3 year
(95% CI)
Mean Yearly Injections
(95% CI)
Overall 53.6
(51.0–56.2)
+5.0
(3.4–6.6) n= 24,039
+3.4
(0.9–5.8) n= 17,928
+1.1
(-5.3 to 7.5)
n= 13,012
5.4
(4.6–6.2)
PRN (n= 21,612) 53.0
(50.0–56.0)
+3.5
(2.0–5.0) n= 20,247
+1.3
(-1.6 to 4.2) n= 14,408
−1.9
(-9.8 to 6.0)
n= 11,714
4.7
(4.0–5.5)
Treat-and-extend (n= 2566) 52.0
(46.5–57.6)
+8.8
(5.8–11.8) n=1539
+6.7
(3.2–10.1) n= 2521
+5.4
(-4.1 to 14.9)
n= 1298
6.9
(5.6–8.2)
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with the PRN ranibizumab group (7.0 versus 5.8, P < .001) but re-
quired fewer clinic visits (10.8 versus 9.0, P < .001). The authors
commented that the observed VA diﬀerences are likely to be related to
more frequent injections with aﬂibercept, suggesting that ranibizumab
should also be delivered by ﬁxed dosing or treat-and-extend posology.
There was a more pronounced initial rise in visual acuity in the loading
phase with aﬂibercept than ranibizumab which warrants further in-
vestigation, preferably controlling for baseline characteristics and
number of injections in the ﬁrst 12 weeks.
TERRA is a real-world observational study being conducted in
England and Wales, which quantiﬁes both the resource use and early
clinical outcomes of a treat-and-extend regimen of ranibizumab for
neovascular AMD. An interim report found that treat-and-extend was
compatible with one-stop services, which can be less resource intensive
than two-stop (separate assessment and injection) services, and may
provide a dosing regimen beneﬁcial to both patients and resource use in
UK clinical practice (Yang et al., 2017).
3.4. Comparing real-world outcomes with diﬀerent anti-VEGF agents
Randomised controlled trials are the preferred method for com-
paring the eﬃcacy and safety for diﬀerent interventions for a disease
process. However, real-world datasets can provide complementary in-
formation especially if the sample sizes are large and inclusion criteria
are more representative of the general population. Caution does have to
be exercised when interpreting real-world comparisons due to the po-
tential for unmatched baseline characteristics and introduction of se-
lection, performance, detection, attribution and reporting bias.
Prospective studies are likely to be more robust than retrospective
analyses.
The FRB! Investigators (Gillies et al., 2016) directly compared VA
and injection frequency outcomes between eyes receiving ranibizumab
or aﬂibercept for nAMD in routine clinical practice. Treatment-naive
eyes with nAMD that commenced intravitreal ranibizumab or aﬂi-
bercept between December 1, 2013, and January 31, 2015 were in-
cluded. Eyes were matched at baseline for VA, age, and CNV size. Eyes
that switched or discontinued treatment were included with their last
observation carried forward. There were 394 eyes (197 treated with
ranibizumab and 197 with aﬂibercept) from 372 patients identiﬁed.
Baseline parameters were well matched. The mean (SD) VA of ranibi-
zumab-treated eyes increased from 58.6 (20.3) LogMAR letters at
baseline to 62.3 (23.9) (+3.7 [95% CI 1.4–6.1]) letters (P = .001),
compared with 58.9 (19.2) letters at baseline to 63.1 (21.5) (+4.26
[95% CI 2.0–6.5]) letters (P < .001) for eyes receiving aﬂibercept. The
diﬀerence in change in crude VA of 0.6 letters between the 2 groups
was not statistically signiﬁcant (P = .76), nor was the diﬀerence in
adjusted mean VA of the 2 groups (P = .26). In completers, the mean
(SD) numbers of injections (8.1 [2.1] versus 8.0 [2.3]; P = .27) and
visits (9.6 [3.0] versus 9.5 [3.1]; P = .15) did not diﬀer between the
groups. The FRB! Investigators identiﬁed that VA outcomes at 12
months did not diﬀer between ranibizumab and aﬂibercept treated eyes
in this observational study, nor was a diﬀerence in treatment frequency
found.
This observation has been replicated in a large retrospective US real-
world dataset. Electronic medical records were used to identify rani-
bizumab or aﬂibercept-treated nAMD eyes with 12 months follow-up
from ﬁrst prescription. A total of 3350 ranibizumab and 4300 aﬂi-
bercept treatment-naive eyes were included. Treatment naïve ranibi-
zumab patients were slightly older than aﬂibercept patients (47.3% vs
39.9%, respectively, were aged>85 years) with slightly lower baseline
mean (SD) study eye VA [57.5 (21.2) versus 58.5 (20.7); P= .025]. At
month 12, mean (SD) change from index in VA letter score was −0.30
(14.8) for ranibizumab and−0.19 (14.7) for aﬂibercept (P= .81). Eyes
received a similar number of injections during follow-up. The mean
(SD) number of ranibizumab and aﬂibercept injections were 6.70 (2.54)
and 7.00 (2.40), respectively (P < .0001). Ranibizumab and
aﬂibercept treatment yielded comparable VA outcomes in nAMD eyes
with similar treatment patterns over 12 months in real-world clinical
practice (Lotery et al., 2017).
3.5. Systemic safety outcomes
Safety concerns regarding intravitreal anti-VEGF therapies remain
unresolved. Systemically delivered anti-VEGF agents are reported to
increase blood pressure and risk of thromboembolic events (Kamba and
McDonald, 2007). There is a long-running controversy whether in-
travitreal delivery of anti-VEGF drugs cause the same problems. Recent
meta-analyses of systemic cardiovascular adverse events in patients
receiving intravitreal anti-VEGF therapy have yielded conﬂicting re-
sults (Avery and Gordon, 2016; Virgili et al., 2014). To date, none of the
published randomised controlled trials of anti-VEGF therapy for neo-
vascular AMD had adequate power to rule out small increases in the risk
of systemic adverse events that patients might ﬁnd signiﬁcant (Esen
et al., 2016). Additionally, patients with recent cardiovascular events
were excluded from pivotal clinical trials (Brown et al., 2006; Rosenfeld
et al., 2006; Schmidt-Erfurth et al., 2014). An eﬀort to evaluate sys-
temic safety issues of these agents is a priority of post-marketing sur-
veillance. In a recent meta-analysis of real-world outcomes of in-
travitreal ranibizumab for neovascular AMD, the included studies had
limited data on systemic safety outcomes (Kim et al., 2016). Linking
real-world registries of intravitreal anti-VEGF therapy with national
databases of hospital admissions/cardiovascular events could poten-
tially answer these questions (see Section 5.5).
3.6. Ocular safety outcomes
The most feared ocular complication of intravitreal anti-VEGF
therapy is endophthalmitis. A meta-analysis of clinical trial and real-
world data on infectious endophthalmitis after intravitreal anti-VEGF
injections for any indication identiﬁed 197 cases out of 350,535 in-
travitreal anti-VEGF injections (0.056%). The most common organisms
isolated were coagulase-negative Staphylococcus (38%) and
Streptococcus species (29%). The reported rate of endophthalmitis after
intravitreal anti-VEGF injections was low although it is likely this is an
underestimate as included studies may not have captured all cases.
Streptococcus species represent the causative organism of en-
dophthalmitis after intravitreal VEGF injections at a higher rate than
rates reported in the literature for endophthalmitis following most in-
cisional intraocular surgeries. Among patients with endophthalmitis
after intravitreal anti-VEGF injection, endophthalmitis caused by
Streptococcus species is associated with poorer visual acuity outcomes
than endophthalmitis caused by coagulase-negative Staphylococcus and
culture-negative cases (Fileta et al., 2014).
The reported rate of endophthalmitis in a meta-analysis of real-
world outcomes of intravitreal ranibizumab for the treatment of neo-
vascular AMD was 17 of 66,176 intravitreal injections (0.026%) (Kim
et al., 2016). This is likely an underestimate due to incomplete capture
of safety outcomes in some real-world registries, this highlights the
importance of an agreed standard minimum dataset (see Section 5.1).
The FRB! investigators recommended reporting the “per patient”
risk of endophthalmitis with intravitreal anti-VEGF therapy. Some pa-
tients in their registry had been treated for up to 10 years and had
received over 60 injections. In other circumstances, in which only a
single intervention is necessary, such as cataract surgery, it may be
adequate just to report endophthalmitis rates “per procedure”. The “per
procedure” incidence of infectious endophthalmitis after intravitreal
injections of ranibizumab was reported at 0.05% in the MARINA clin-
ical trial, whereas the endophthalmitis rate “per patient” was 1.0% over
a 2-year period (Kaiser et al., 2007). In a prospective real-world FRB!
study from 2006 to 2016, the incidence of infectious endophthalmitis
“per procedure” was 18 out of 88,150 injections (1/4897 injections
[0.020%]; 95% CI, 0.012–0.032%) with no diﬀerence identiﬁed
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between diﬀerent anti-VEGF medications, whereas the rate “per pa-
tient” increased over the number of injections from 0.055% after 10
injections to 0.843% after 60 injections (Daien et al., 2018). However,
the analysis did not detect a clinically relevant increase in the risk per
injection as the number of injections increased, suggesting the risk of
endophthalmitis was linear and not exponential. One quarter of cases
with infectious endophthalmitis had lost more than 10 LogMAR letters
compared with pre-endophthalmitis visual acuity a year after the ad-
verse event. Much longer follow-up was possible with a real-world
study compared with the seminal clinical trials.
The FRB! investigators also assessed the incidence of non-infectious
endophthalmitis which developed in 11 of 88,150 injections from 2006
to 2012 (1/8013 injections [0.012%]; 95% CI, 0.006–0.022%). The
incidence of non-infectious endophthalmitis was higher for bev-
acizumab (8/9931, 0.081%) compared with ranibizumab (3/54,776,
0.005%; P= .005) and aﬂibercept (0/23,425; P= .016), with no sig-
niﬁcant diﬀerence observed between ranibizumab and aﬂibercept
(P= 1.0) (Daien et al., 2018). The pathophysiology of non-infectious
endophthalmitis after anti-VEGF therapy is not fully understood and
could involve an immune reaction to the drug itself or impurities
gathered in manufacture, preparation, storage or delivery of the agent.
Limitations of this analysis include potential under-reporting of uni-
dentiﬁed cases and that culture-negative cases of infective en-
dophthalmitis could have been labelled as non-infectious.
Other potential ocular complications of intravitreal anti-VEGF in-
jections include retinal detachment, cataract and raised intraocular
pressure. There is the potential to link real-world registries to in-
vestigate the risk of these adverse ocular events (see Sections 4.5 and
5.5).
3.7. Quality of life indices
From the patient and payer perspective, a more important treatment
outcome than distance visual acuity is quality of life, which reﬂects not
only changes in vision but also the impact of therapy on activities of
daily living and emotional well-being. Over 1000 participants involved
in the ANCHOR and MARINA Phase III clinical trials of anti-VEGF
therapy for neovascular AMD demonstrated a gain in vision-related
quality of life (VRQoL) with treatment over 24 months using the 25-
item National Eye Institute Visual Functioning Questionnaire (NEI-
VFQ-25) (Bressler et al., 2010). However, the NEI-VFQ-25 has been
demonstrated to not be psychometrically valid in its native form
(Marella et al., 2010).
In contrast, the Impact of Vision Impairment (IVI) proﬁle is a VRQoL
instrument that has been shown to be reliable, responsive to interven-
tions and has been rigorously validated using modern psychometric
methods, such as Rasch analysis, for diﬀerent ocular conditions and
diﬀerent levels of visual function (Lamoureux et al., 2007). The IVI
consists of 28 items that cover 3 domains: ‘‘mobility and in-
dependence’’, ‘‘emotional well-being’’, and ‘‘reading and accessing in-
formation’’. The IVI has advantages relating to content, quality and
practicality over other validated patient reported outcome measures
(PROMs) such as the Metamorphopsia Questionnaire, Macular Disease
Quality of Life, Daily Living Tasks Dependent on Vision, and NEI-VFQ-
25 (Rodrigues et al., 2016).
The IVI was used to determine the impact of anti-VEGF treatment as
provided in standard medical practice on VRQoL in 169 patients over
12months at a large public eye hospital in Australia (Finger et al.,
2014a). Those who lost> 10 LogMAR letters (11%) reported worse
VRQoL at 12 months on the accessing Information and mobility sub-
scales (P= .007 and P= .050, respectively). Conversely, those who
gained>10 LogMAR letters (24%) reported better VRQoL on the ac-
cessing information and emotional well-being subscales (P= .009 and
P= .008, respectively). Patients who did not experience a signiﬁcant
change in VA reported no change in their VRQoL. In multivariate
analyses, only a change in VA but not whether the better or worse eye
was treated predicted a change in VRQoL on the accessing Information
(P= .004) and the emotional well-being (P= .008) subscales. Future
real-world studies would beneﬁt from measurement and standardisa-
tion of VR-QOL outcomes (see Section 5.1).
4. Novel observations
4.1. Time to reactivation of neovascular AMD when anti-VEGF treatment is
stopped
The seminal clinical trials of intravitreal anti-VEGF therapy for
neovascular AMD were 2 years in duration (see Section 1.3). They were
not designed to provide evidence on the potential risk of recurrence of
disease activity after cessation of anti-VEGF therapy and the impact on
visual outcomes.
Initial real-world evidence relating to the risk of disease reactivation
was provided in a retrospective review of observational data from a
single Australian private practice (Vaze et al., 2014). Eyes in which
treatment with intravitreal ranibizumab or bevacizumab was dis-
continued for more than 3 months during a 3-year period from 2006 to
2009 were analysed. Of 115 eyes from 103 patients, 91% of eyes de-
veloped reactivation of neovascular AMD with a signiﬁcant decline in
the mean VA from 58.2 LogMAR letters at the time of last injection to
50.2 letters at the time of recurrence (p < .001, paired t-test). Of the
recurrences, 82% were picked up on routine ﬁxed interval examination,
while 18% returned earlier with metamorphopsia or decrease in vision.
The mean number of injections received before treatment dis-
continuation was 5.6 (range 3.0–22.0). The median time to disease
reactivation after treatment discontinuation for at least 3 months was
33.1 weeks (95% CI: 28.1 to 40.9). Only 9% of eyes did not show any
signs of disease reactivation with a mean follow-up of 18 months.
Analysis of a large real-world dataset of over 2000 eyes in the FRB!
registry that received intravitreal ranibizumab for neovascular AMD
according to a treat-and-extend regimen conﬁrmed a high rate of dis-
ease reactivation over time after disease stability had been achieved. As
Table 4 illustrates, treatment intervals beyond 12 weeks appear to be
associated with an increased risk of disease reactivation, with the risk of
reactivation reaching 36.5% per visit at treatment intervals of 20 weeks
(Essex et al., 2016). This translated into an increased risk of losing≥15
LogMAR letters with treatment intervals greater than 12 weeks.
Table 4
Frequency and adjusted marginal risk of ﬁrst reactivation of choroidal neovascularisation at each treatment interval, by treatment interval. CI= conﬁdence interval. Opportunities for
reactivation includes visits for all eyes prior to the ﬁrst reactivation. Modiﬁed from Table 3 of Treatment patterns and visual outcomes during the maintenance phase of treat-and-extend
therapy for AMD (Essex et al., 2016).
Interval of ﬁrst reactivation Opportunities for reactivation Frequency, n % Risk per visit (95% CI) Change in risk from previous level, %
4 weeks 1157 128 9.9 (8.0, 12.3) 0
6 weeks 2100 262 12.1 (10.4, 14.1) 2.2
8 weeks 3019 365 14.5 (12.8, 16.4) 2.4
12 weeks 2650 299 15.3 (13.3, 17.5) 0.8
16 weeks 744 109 20.9 (16.9, 25.5) 5.6
20 weeks 467 126 36.5 (30.5, 43.0) 15.6
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A large UK observational study analysed the time to re-treatment
after a pause in therapy for neovascular AMD in a large dataset of
12951 eyes receiving 92976 intravitreal ranibizumab injections be-
tween 2008 and 2012 mainly using a PRN approach (Madhusudhana
et al., 2016). Following a treatment free interval (TFI) of 3 months, 6
months, 9 months and 12 months, 77%, 56%, 43% and 34% of these
eyes required retreatment after an additional 12 months of follow-up.
As Table 5 demonstrates, disease reactivation led to a mean decrease in
VA which did not fully recover on restarting treatment.
It might not be advisable to discharge patients or consider them
‘cured’ despite no signs of activity for even after a year of inactivity.
Such eyes at the very least require observation and there might be an
argument for continued therapy at capped intervals upon reaching
disease stability to prevent long-term recurrences in eyes with a good
initial response to treatment, especially with longer acting anti-VEGF
agents in the pipeline.
4.2. Treating patients with baseline visual acuity better than 6/12 (70
LogMAR letters)
In the UK, the National Institute of Health and Care Excellence
(NICE) advises whether drugs are cost-eﬀective for use in the National
Health Service. In 2008, NICE only recommended treatment with in-
travitreal ranibizumab for neovascular AMD if the baseline VA was in
the range 6/12–6/96 (NICE, 2008), consistent with the inclusion cri-
teria of the pivotal MARINA and ANCHOR registration clinical trials
(Kaiser et al., 2007; Rosenfeld et al., 2006; Brown et al., 2006). In 2014,
NICE applied the same baseline VA restrictions to use of intravitreal
aﬂibercept for neovascular AMD (NICE, 2013).
The proportion of eyes with neovascular AMD detected with base-
line VA better than 6/12 (70 LogMAR letters) has increased over time,
due to increased awareness of the disease and surveillance of high-risk
fellow eyes during treatment of the ﬁrst eye (Barthelmes et al., 2014;
Zarranz-Ventura et al., 2014). It seemed reasonable that treating at
baseline VA better than 6/12 is more likely to result in a patient re-
taining driving vision and maintaining a better quality of life (Keenan
et al., 2013). It is unlikely that a clinical trial will now be conducted to
replicate the ANCHOR and MARINA clinical trial design for study eyes
with better than 6/12 vision at baseline, where the control arm received
deferred treatment. Real-world registries can provide useful evidence in
this context.
The UK AMD EMR Users Group evaluated the eﬃcacy of initiating
treatment with ranibizumab for neovascular AMD in eyes with baseline
VA better than 6/12 (> 70 LogMAR letters) in routine clinical practice
in the UK National Health Service. Some of the commissioning groups
in the UK had provided funding to treat patients with better than 6/12
baseline VA. Anonymised structured data were collected from 14 UK
centres. The primary outcome was the mean VA at year 1, 2 and 3. A
total of 754 of 11 135 patients had baseline VA better than 6/12 and at
least 1-year of follow-up. All eyes with baseline VA better than 6/12
maintained superior mean VA than the eyes with baseline VA between
6/12 to 6/24 at all time-points for at least 2 years (globally adjusted p-
values< 0.001 in year 1 and 2). Fewer than 50 eyes had baseline VA
better than 6/12 at baseline and 3 years follow-up. The authors re-
ported that the signiﬁcantly better visual outcome in patients who were
treated with good baseline VA had implications for future policy re-
garding funding treatment for nAMD (Lee et al., 2015).
Data can also be evaluated from other countries where arbitrary
baseline VA restrictions are not applied. Five year real-world outcomes
of intravitreal ranibizumab for neovascular AMD in 549 eyes from the
FRB! database mainly set in Australia, stratiﬁed by baseline VA are il-
lustrated in Fig. 2 (Gillies et al., 2015a). Eyes with better baseline VA
maintain good vision for longer although there is less scope for im-
provement in VA because of a ceiling eﬀect.
NICE is currently evaluating its guidance regarding intravitreal anti-
VEGF treatment for neovascular AMD in the UK for patients presenting
with baseline VA better than 6/12. It is important they and other ad-
visory bodies evaluate both clinical trial and real-world evidence to
come to decisions in the best interests of patients.
4.3. Second aﬀected eyes had better visual acuity outcomes after anti-VEGF
treatment
An analysis of 1207 eyes from 1033 patients with neovascular AMD
treated in Gloucestershire, United Kingdom with intravitreal ranibi-
zumab between 2008 and 2012 identiﬁed median baseline VA was
signiﬁcantly better for second treated than ﬁrst treated eyes (66 versus
56 LogMAR letters respectively; p < .0001) (Keenan et al., 2013). A
slow decline in VA in one eye may go unnoticed if the other eye still has
good vision and patients are likely to seek help more quickly and be
aware of how to access appropriate healthcare services when the
second (better seeing) eye is aﬀected. It is also likely that second eye
involvement would be detected earlier during the regular visits re-
quired for treatment of the ﬁrst aﬀected eye.
The UK AMD EMR Users Group identiﬁed that 1816 (16.3%) of the
total cohort of 11135 patients received intravitreal ranibizumab treat-
ment to the fellow eye between 2008 and 2012 (Zarranz-Ventura et al.,
2014). Over 3 years, mean baseline and ﬁnal VA were 52 LogMAR
letters and 51 LogMAR letters for ﬁrst treated eyes and 62 LogMAR
letters and 57 LogMAR letters for second treated eyes. First treated eyes
gained more vision most likely due to treatment starting at worse
baseline VA, but second treated eyes which had less scope for vision
improvement on average maintained better absolute levels of vision.
When fellow eyes with baseline VA worse than 6/60 were excluded to
restrict analyses to eyes at risk of neovascular AMD, the rate of second
eye involvement was 14.0% per year (42% over 3 years) (Zarranz-
Ventura et al., 2014). The rate of VA loss after the loading phase was
similar in ﬁrst and second treated eyes (1.5 and 2.5 LogMAR letters/
year). The mean number of injections/visits in years 1, 2, and 3 were
similar for ﬁrst and second treated eyes (5.6/8.2, 3.9/8.0, 3.8/8.2 and
5.5/8.7, 3.6/9.4, and 3.8/9.1, respectively).
The FRB! dataset independently corroborated these ﬁndings. Of a
cohort of 1992 patients, 28% had bilateral disease (Barthelmes et al.,
2014). There were 176 participants in which ﬁrst and second eyes had
been diagnosed with neovascular AMD at least 2 months apart with a
minimum of 12 months of follow-up data. Mean baseline VA in ﬁrst
aﬀected eyes was 49.7 LogMAR letters. Mean greatest linear dimension
in ﬁrst eyes was 2840μm (Q1 1500μm, Q3 3500). Median time to di-
agnosis of the second eye was 427 days after the ﬁrst eye. At their index
visit, second eyes had better VA (mean 61.2 LogMAR letters) and
smaller lesion size (mean greatest linear dimension of 2250μm). Twelve
months after commencing intravitreal anti-VEGF treatment with rani-
bizumab, ﬁrst-aﬀected eyes had a mean VA of 56.9 LogMAR letters
(mean 7.2 letter improvement compared with the index visit;
P < .001), whereas second-aﬀected eyes had a mean VA of 65 LogMAR
letters (mean 3.8 letter improvement compared with the index visit;
P < .001). Although a greater mean improvement was observed in ﬁrst
Table 5
Change in mean visual acuity (LogMAR letters). Modiﬁed from Table 2 of Neovascular
age-related macular degeneration database. Report 6: time to retreatment after a pause in
therapy. Br J Ophthalmol. (Madhusudhana et al., 2016). TFI, treatment-free interval.
Mean visual acuity (LogMAR letters)
At the beginning of
treatment-free period
At the time of
retreatment
At ﬁrst visit after
retreatment
TFI 3 months 57.26 54.33 55.43
TFI 6 months 56.90 53.24 54.32
TFI 9 months 56.47 52.29 53.44
TFI 12
months
57.50 53.25 54.27
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eyes, their 12-month mean VA was still less than that of the second eye
group. Choroidal neovascular lesions were diagnosed by the treating
physician as either occult, minimally classic, predominantly classic, or
retinal angiomatous proliferation; all other lesion types were combined
into a single category. Overall, 64% of patients had the same lesion type
in each eye (Cohen kappa= 0.48), indicating fair to good concordance
of lesion type between ﬁrst and second aﬀected eyes (Barthelmes et al.,
2014). It should be noted that there is real-world evidence that anti-
VEGF therapy for neovascular AMD can improve vision-related quality
of life irrespective of whether the worse or better eye is treated (Finger
et al., 2014a).
Although not addressed in randomised controlled trials, second eye
involvement is common. Hence patient education that second eye in-
volvement may occur and regular checks of the second eye during
clinics in which the ﬁrst aﬀected eye is being treated are strongly re-
commended to identify changes early and institute treatment promptly.
Treatment regimens with long intervals (> 12 weeks) between OCT
assessments of the second eye may not be advisable.
4.4. Eﬀect of switching anti-VEGF agents for neovascular AMD
There is debate as to whether switching anti-VEGF agents can oﬀer
therapeutic beneﬁt in treating neovascular AMD, particularly if there is
persistent disease activity despite treatment. The FRB! investigators
examined 12-month outcomes of eyes that received ranibizumab for at
least 12 months before switching to aﬂibercept and followed for at least
12 months after the switch (Barthelmes et al., 2016). A total of 384 eyes
were switched from ranibizumab to aﬂibercept after a mean duration of
39.8 months on the original treatment. The mean VA did not change
from the time of switching treatment (63.4, SD 15.9 LogMAR letters) to
12 months later (63.3 LogMAR letters, SD 16.7). While 10% of eyes
gained 10 or more letters 12 months after the switch, 13% lost the same
amount. The mean number of injections decreased by around one in-
jection in the 12 months after switching (p < .001), with a decrease in
the proportion of choroidal neovascular membrane lesions that were
graded as active. The small proportion (6.9%) of eyes that switched
back again to ranibizumab had already lost a mean of 5.2 letters from
the ﬁrst switch to the switch back and continued to lose vision at a
similar rate for at least 6 months. The mean VA of eyes that switched
treatments from ranibizumab to aﬂibercept was not diﬀerent 12 months
later, although there was a modest increase in treatment intervals and a
somewhat greater proportion of eyes that were graded as inactive after
the switch.
A multicentre, national, electronic medical record database study
was performed in the UK to assess whether there were visual beneﬁts in
switching eyes which had been chronically treated with ranibizumab
for neovascular AMD to aﬂibercept (Lee et al., 2017b). Eyes that had
received six continuous monthly ranibizumab injections which were
then switched to continuous aﬂibercept were matched to those that
received continuous ranibizumab therapy. Matching was performed in
a 2:1 ratio for 1344 patients based on visual acuity 6 months before and
at the time of the switch and the number of previous ranibizumab in-
jections. Patients who were switched to aﬂibercept demonstrated
transiently signiﬁcant improvement in visual acuity that peaked at an
increase of 0.9 LogMAR letters 3 months after the switch, whereas
control patients continued on ranibizumab treatment showed a steady
decline in VA. The VA diﬀerences between the groups were small but
signiﬁcant (P < .05) at 2, 3, and 5 months after the switch. Beginning
at 4 months after the switch, the switch group showed a VA decline
similar to the control group. Switching from aﬂibercept to ranibizumab
was not assessed mainly because this did not represent a large group of
patients as aﬂibercept had been introduced to the market more re-
cently. Importantly, the number of intravitreal injections in the period
after either switching to aﬂibercept or continuing with ranibizumab did
not have to be the same. Therefore, the transient non-sustained im-
provement may have been due to the increase in the frequency of
injections that occurred at the time of the switching rather than the
superiority of one agent over the other.
Real-world registries can collect long-term outcomes data to assess
whether tachyphylaxis is a real phenomenon with intravitreal anti-
VEGF therapy. Well conducted randomised controlled trials could ad-
dress whether combining intravitreal anti-VEGF agents, either con-
currently or sequentially, could potentially take advantage of their
diﬀerent mechanisms of action.
4.5. Rate of posterior capsular rupture in eyes with previous intravitreal
injections
Posterior capsular rupture (PCR) is a complication of cataract sur-
gery that can be associated with signiﬁcantly worse visual outcomes
(Sparrow et al., 2012). The Royal College of Ophthalmologists of Eng-
land National Ophthalmology Database study of cataract surgery for
cases between 2006 and 2010 reported the mean PCR rate was 1.95%
(Day et al., 2015).
The United Kingdom AMD and DR EMR Users Group tested the
hypothesis that previous intravitreal therapy is a predictor of increased
risk of PCR during cataract surgery (Lee et al., 2016). Anonymised data
were extracted for eyes undergoing cataract surgery from 20 UK hos-
pitals using the Medisoft electronic medical records system for cases
performed between 2004 and 2014. Data were available on 65836
cataract operations, of which 1935 eyes had received previous in-
travitreal injections (2.9%). Of these injections, 80% were intravitreal
anti-VEGF therapy for neovascular AMD. Univariate regression identi-
ﬁed patient age, advanced cataract, junior cataract surgeon grade, and
the number of previous intravitreal injections were associated with
increased risk of PCR. By considering the number of previous in-
travitreal injections as a continuous variable and adjusting for other
signiﬁcant independent predictors, the odds ratio for PCR per in-
travitreal injection was 1.04 (P= .016). Repeat analysis considering
intravitreal injections as a categorical variable identiﬁed 10 or more
previous injections were associated with a 2.59 times greater likelihood
of PCR (P= .003) again after adjusting for other signiﬁcant in-
dependent predictors. Possible explanations include inadvertent crys-
talline lens capsule trauma and zonular trauma either directly or from
local scleral deformation at the time of injection. Identiﬁcation of cases
at higher risk of PCR assists preoperative planning and allows patients
to be better informed about potential surgical risks (Lee et al., 2016).
Two independent studies have supported this ﬁnding. An increased
rate of PCR was identiﬁed during cataract surgery in 197 eyes with
prior intravitreal injections compared with matched control eyes
without prior injections (3% versus 0%, P= .030) in a retrospective
cohort analysis of cataract surgery procedures performed by experi-
enced surgeons at the Duke Eye Center in North Carolina, USA from
2005 to 2012 (Hahn et al., 2016). An analysis of Moorﬁelds electronic
databases identiﬁed 62 994 cataract surgery procedures undertaken
across its UK Trust sites between 2012 and 2015, with 1035 (1.64%)
eyes having received previous intravitreal therapy. Prior intravitreal
injection was associated with an increased risk of PCR (P= .037) with
an odds ratio of 1.66 (Shalchi et al., 2017).
5. Future directions
5.1. Deﬁning a minimum set of standard real-world outcome measures for
neovascular AMD
A consensus regarding a standardised set of minimum outcome
measures for neovascular AMD was required for healthcare profes-
sionals to assess their performance objectively and compare it with
others to drive improvements in clinical practice. Such a standardised
outcome set might also help patients to make well-informed decisions
about their treatment and allow insurers or commissioners to under-
stand the quality and value of care that they are funding. Similar
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consensus minimum datasets have been used in other areas of medicine,
for example coronary heart disease, to support improvements in global
standards (McNamara et al., 2015).
Recommendations from a working group of international experts in
AMD outcomes registry development and patient advocates were fa-
cilitated by the International Consortium for Health Outcomes
Measurement (ICHOM). A modiﬁed Delphi technique was employed to
drive consensus decisions. Potential outcomes were identiﬁed through a
review of outcomes collected by existing registries and reported in
major clinical trials. Outcomes were reﬁned by the working group and
selected based on impact on patients, relationship to good clinical care
and feasibility of measurement in routine clinical practice (Rodrigues
et al., 2016).
Standardised measurement of the outcomes in Table 6 below were
recommended by the ICHOM working group. It was recommended that
distance visual acuity readings be measured using a logarithm of the
minimal angle of resolution (LogMAR) chart, although other measure-
ment systems may be used and subsequently converted to LogMAR
visual acuity. Measuring mean change in visual acuity after starting
treatment was recommended because it has become the primary out-
come of phase III clinical trials for neovascular AMD. However, ob-
servational studies have found that, because of ceiling eﬀects, this may
skew results in favour of services that detect the disease and start
treatment late, since eyes with worse vision have more to gain com-
pared with eyes starting with good vision, which may not gain any-
thing. Therefore the proportion of eyes with stable vision, good vision
(better than 6/12; 70 LogMAR letters), and poor vision (worse than 6/
60; 35 LogMAR letters) should also be measured.
Patient reported outcome measures (PROMS) are recorded using the
brief Impact of Vision Impairment (IVI) questionnaire. The IVI has been
validated speciﬁcally in patients with AMD and found to have appro-
priate content and reliability; it has also undergone Rasch analysis. In
practical terms, the IVI is also free to use (for non-commercial purposes)
and takes approximately 15min to complete using paper, computer or
touch screen–adapted versions. A guide to scoring and analysis of the
IVI is included in the ICHOM Macular Degeneration Standard Set
Reference Guide (available at http://www.ichom.org/medical-
conditions/macular-degeneration/). The developers of the IVI are
willing to provide advice on the process of translation and validation if
needed.
Using the same methodology, the ICHOM working group re-
commended recording the following baseline clinical characteristics to
enable risk adjustment: age, sex, ethnicity, smoking status, visual acuity
in both eyes, type of macular degeneration, presence of geographic
atrophy, subretinal ﬁbrosis or pigment epithelial detachment, previous
AMD treatment and ocular comorbidities (Rodrigues et al., 2016).
The resultant minimum core dataset is inevitably a compromise
between intricate details that may be useful for comparison and the
practicalities and burden of data collection in busy clinics. Interested
care providers should therefore add additional outcomes to meet their
speciﬁc requirements. However, we would encourage all centres to
collect the minimum dataset described here recommended by the
ICHOM working group.
5.2. Developments in statistical analyses to address missing data
Loss to follow-up (LTFU) in longitudinal studies may result in biased
estimates if patients who drop out are not appropriately accounted for
in the ﬁnal analysis. The STROBE checklist (STROBE, 2007) for ob-
servational studies requires researchers to report and justify their
handling of LTFU.
Although investigators strive to limit LTFU, in most instances they
fail to achieve complete follow-up of all included patients (Wood et al.,
2004). A cut-oﬀ of 20% of LTFU is used in Evidence-Based Medicine
‘‘Levels of Evidence’’ (Centre-Evidence-Based-Medicine, 2009) to se-
parate ‘‘high’’ and ‘‘low’’ quality RCTs. As depicted in Table 7, theTa
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proportion of patients LTFU in neovascular AMD observational studies
ranged from 17 to 34% at 1 year to 49–54% at 4–5 years.
To draw inferences from LTFU data, it is necessary to make some
assumptions. A common method of analysis restricts attention to in-
dividuals for whom the outcome of interest is observed (complete case
analysis). This makes the analysis simple, but the implicit assumption
that the excluded individuals do not diﬀer systematically in any way
from the included individuals is restrictive and unlikely to be true in
many cases (Briggs et al., 2003). Nonetheless, many observational
studies of anti VEGF-therapy in nAMD patients have used complete case
analysis (Cohen et al., 2013; Finger et al., 2013; Gabai et al., 2014;
Heimes et al., 2011; Kumar et al., 2011; Pushpoth et al., 2012). One
approach is to look at a matched cohort who completed follow-up and
had similar characteristics at the time of LTFU.
A common method used to deal with patients LTFU is to take the
last observation carried forward (LOCF), where the latest observed
value is carried forward to the end of the study. (Chavan et al., 2014;
Frennesson and Nilsson, 2014; Ross et al., 2013; Silva et al., 2013; Wolf
and Kampik, 2014; Wykoﬀ et al., 2017). LOCF was initially applied to
randomised controlled trials in acute diseases such as infection where
the patient's status was expected to improve after treatment initiation.
In this case, the LOCF method penalises the group with more LTFU.
However, in chronic diseases where the treatment goal is to slow pa-
tient decline, LOCF may lead to artiﬁcially high rates of treatment
beneﬁt in groups with more LTFU (e.g. cognitive decline in dementia)
(Molnar et al., 2008). Using LOCF in neovascular AMD presumes that
the visual acuity would have been stable from the point of dropout to
the study endpoint, which is not always the case (Fig. 5).
Suggested strategies to address missing outcome data in neovascular
AMD observational studies include multiple imputation or mixed eﬀect
models. Brieﬂy, multiple imputation creates sets of complete datasets,
each of which is then analysed using standard statistical techniques and
the results pooled. This has several advantages over single imputation
methods like LOCF. By pooling results from multiple imputed datasets,
it takes into account the inherent uncertainty in the value of the missing
data and the variation both within and between imputations (Li et al.,
2015). However, its implementation in longitudinal data is not
straightforward if visits are at irregular intervals. Mixed-eﬀects re-
gression models for repeated measurements can be used to analyse data
without the need to impute missing data and are better suited to data
that do not have regular measurement intervals. Such models make use
of all observed measurements, including subjects that are LTFU.
There is a need for consensus on the statistical methods used to
address LTFU in real-world observational studies. This is particularly
important when comparing interventions. Regardless of the statistical
technique used to address LTFU, a safe option may be to perform a
sensitivity analysis to ensure the validity of outcomes.
5.3. Mining big data and deep learning
The European Medicine Agency reported that ‘big data’ could be
characterised by the ‘5 Vs’: Volume, variety, veracity, velocity and
value. (E.M.A, 2016). Big data comprises massive data sets of far
greater ‘volume’ and ‘variety’ than traditional data sets and may re-
present both breadth of data from large numbers of individuals and
depth of data on each individual. ‘Veracity’ refers to uncertainty of the
quality and robustness of data from diﬀerent sources. However, the
sheer size and variety of big data may overcome a lack of certainty in
data sets. Today, data are accumulating at an unprecedented ‘velocity’
and can be transmitted and analysed in real-time. Big data provides
‘value’ by enabling generation of information and knowledge to provide
new insights, reveal hidden and rare associations, and increase eﬃ-
ciencies. Sources of real-world data include medico-administrative da-
tabases, registries, electronic medical records, surveys and patient
generated data, for example from smartphone applications (Salathe
et al., 2012; Salathe and Khandelwal, 2011). Some real-world data can
be deﬁned as big data when the volume becomes massive.
Optical coherence tomography (OCT) imaging is used to determine
disease activity when treating neovascular AMD in routine clinical
practice. Within each image are millions of data points. It is possible to
link this big data from imaging with clinical trial or registry outcomes
using deep learning techniques. For example, the potential for machine
learning to predict visual outcomes from structural (OCT imaging) and
functional (BCVA) assessments during the initiation phase in 614 pa-
tients receiving intravitreal ranibizumab for neovascular AMD in the
HARBOR clinical trial has been assessed (Schmidt-Erfurth et al., 2017).
Monthly spectral-domain OCT macular volume scans were processed by
fully automated computational image analysis. The pre-speciﬁed
quantitative OCT biomarkers and BCVA measurements at baseline and
months 1, 2, and 3 were used to predict BCVA at 12 months using
random forest machine learning. The most relevant biomarker for
BCVA was the horizontal extension of intraretinal ﬂuid in the foveal
region, whereas subretinal ﬂuid and pigment epithelial detachment
ranked low. In predicting functional outcomes, the model's accuracy
increased in a linear fashion with each month. If only the baseline visit
was considered, the accuracy was R2= 0.34. At month 3, ﬁnal visual
acuity outcomes could be predicted with an accuracy of R2=0.70.
Whilst yielding interesting results, the random forest machine learning
approach used in this analysis was limited in that the biomarkers
searched for had to be pre-speciﬁed (Schmidt-Erfurth and Waldstein,
2016).
Table 7
Examples of loss to follow-up rate in observational studies of anti-VEGF therapy in neo-
vascular age-related macular degeneration.
Endpoint Loss to follow-up
rate
Observational study in neovascular AMD,
Country
1 year 17% (Gupta et al., 2010), USA
21% (Hjelmqvist et al., 2011), Sweden
26% (Finger et al., 2013), Germany
34% (Tufail et al., 2014), UK
2 year 16% (Abedi et al., 2014), Australia
28% (Menghini et al., 2012), Switzerland
34% (van Asten et al., 2015), Netherlands
47% (Holz et al., 2016), European countries mainly
4 year 49% (Pushpoth et al., 2012), UK
5 year 54% (Gillies et al., 2015a), Australia, New Zealand,
Switzerland
Fig. 5. Eﬀect of last observation carried forward at various times of loss to follow-up in a
typical case of neovascular age-related macular degeneration treated with anti-vascular
endothelial growth factor drugs. LOCF=Last observation carried forward; LTFU=Lost
to follow-up. Using LOCF in age-related macular degeneration presumes that the visual
acuity would have been stable from the point of dropout to study endpoint. The general
pattern of treated neovascular AMD evolution is a sharp improvement of mean visual
acuity in the 6 ﬁrst months of therapy and then a plateau which either stabilises or slowly
decreases over time. LOCF will either overestimate or underestimate the outcomes.
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There has been a signiﬁcant step forward in deep learning techni-
ques with the advent of many-layered neural networks which can be
trained to develop convolutional matrices and have the potential to
identify novel biomarkers. Convolutional neural networks were in-
spired by the organisation of the visual cortex. Seminal research con-
ducted by Hubel and Wiesel in the 1960s identiﬁed that diﬀerent in-
dividual neurons in the visual cortex ﬁred only in the presence of visual
stimuli of edges at certain orientations (Hubel and Wiesel, 1963). For
example, some neurons ﬁred when exposed to vertical edges and some
when shown horizontal or diagonal edges. They discovered that all of
these neurons were organised in a columnar architecture that together
produce visual perception. This idea of specialised components inside a
system having speciﬁc tasks is the basis of convolutional neural net-
works. Deep learning approaches have progressed due to a number of
major leaps forward, not only with convolutional networks, but also the
exponential rise of computing power with graphics processing units,
non-linear activation functions for solving the vanishing gradient pro-
blem, and improved algorithms for stochastic gradient descent
(Murphy, 2012). However, often these systems must be exposed to
several tens of thousands of examples before this type of deep learning
can be used eﬀectively. For example, at the University of Washington,
Seattle, investigators have sought to determine if deep learning could
be utilised to distinguish normal OCT images from those in patients
with any form of AMD (Lee et al., 2017). They selected 52,690 normal
macular OCT images and 48,312 AMD macular OCT images and linked
them to clinical data from their EMR system. A 21-layer deep neural
network was trained to categorise images as either normal or having
AMD. Peak sensitivity and speciﬁcity with optimal cutoﬀs were 92.6%
and 93.7% respectively. The trained deep learning model learned the
OCT features directly from the images themselves without the need for
image-speciﬁc labels. The investigators identiﬁed through occlusion
masking that the model was most dependent on pathologic areas to
make a diagnosis of AMD. The authors reported that these ﬁndings have
important implications in utilising OCT in automated screening and the
development of computer aided diagnostic tools in the future.
Google DeepMind have collaborated with Moorﬁelds Eye Hospital
in London in an exploratory study to investigate whether computer
algorithms can detect and classify pathological features on eye imaging,
including digital fundus photographs and OCT scans (De Fauw et al.,
2017). Approximately 1 million images from the past decade will be
assessed. A successful outcome of this exploratory study will provide
novel image analysis algorithms to identify and quantify speciﬁc pa-
thological features in eye imaging using validated methods and expert
clinical consensus. One issue can be the small proportion of mis-
diagnosed cases in real-world registries. Therefore, additional manual
labels will be produced by experts to select images. Google DeepMind
will use deep learning techniques to develop the algorithm, including
but not limited to convolutional neural networks.
Deep learning approaches could be extended to link a range of
multimodal imaging modalities with outcome registries. The UK EMR
Users group is planning to link EMR outcomes with information from
over 40 million OCT images which should provide new insights into
prediction of outcomes in individuals and populations.
5.4. Linking genotypes with outcomes data
Pharmacogenetic associations with anti-VEGF treatments may in-
ﬂuence the visual outcomes in neovascular AMD. A prospective cohort
study was carried out to determine the association of genetic variants of
the VEGF-A gene with the outcome of anti-VEGF treatment in neovas-
cular AMD. From an Australian registry, 201 consecutive patients re-
ceiving anti-VEGF injections for neovascular AMD with 12 months
follow-up were identiﬁed (Abedi et al., 2013). Seven tagged single
nucleotide polymorphisms (SNPs) in the VEGF-A gene were selected
and examined. In patients with the T allele in tagged SNP rs3025000,
there was a signiﬁcantly better visual outcome at 6 months. The authors
reported visual outcomes of patients harbouring the T allele at SNP
rs3025000 were comparable with those of pivotal clinical trials but
with fewer injections, perhaps making the treatment more cost-eﬀective
in certain subgroups of patients (Abedi et al., 2013).
Evidence on genetic predictors of anti-VEGF treatment response in
neovascular AMD has been reviewed. No meta-analysis of results was
possible because of the lack of randomised controlled trials, varying
treatment regimens, suboptimal reporting and small sample sizes
(Finger et al., 2014b). For genetic factors, most evidence to date has
been generated for SNPs in complement factor H (CFH) and VEGF-A
genes. Just under 50% of the SNPs assessed in the CFH gene and 15% of
the SNPs assessed in the VEGF-A gene were found to be associated with
visual outcomes or the number of injections required during follow-up.
Based on the limited studies conducted thus far, the evidence suggests
that the underlying genotype of known AMD risk associated genes (e.g.
CFH, VEGF-A and ARMS2/HTRA1) are less important in predicting
treatment outcomes than presenting clinical features. Linking large-
scale real-world outcome registries with genotyping oﬀers the possibi-
lity of targeting therapies for maximum beneﬁt.
Beyond genomics, there is the potential to link metabolomic proﬁles
of patients with treatment outcomes to identify biomarkers and novel
therapeutic targets for neovascular AMD (Lambert et al., 2016). Plasma
metabolite changes predominantly in the glycerophosphorolipid
pathway have been identiﬁed in patients with AMD compared with
controls using nuclear magnetic resonance (Lains et al., 2017). Lim-
itations of this study included the cross-sectional design, an almost
exclusively White population and no validation cohort. Further work in
this area is warranted.
5.5. Linking registries to obtain safety data
Registries may be linked to other databases to allow analysis of
systemic safety outcomes. Ng et al. identiﬁed patients aged 40 years
and over who received treatment with intravitreal anti-VEGF injections
for neovascular AMD from 2008 to 2011 at the Singapore National Eye
Centre. They used a national record linkage database to identify pa-
tients who developed myocardial infarction, stroke and all-cause mor-
tality after the ﬁrst injection, excluding those with previous myocardial
infarction or stroke at baseline from the respective analysis, and com-
pared them with the total Singaporean population. They found that the
incidence of myocardial infarction, stroke, and death in this cohort of
patients over the age of 40 treated with intravitreal anti-VEGF therapy
was low and was not signiﬁcantly higher than the age-adjusted in-
cidence of these events in the general Singaporean population (Ng
et al., 2015). It should be noted that these conclusions cannot be ex-
tended to patients who have had previous thromboembolic events as
they were excluded from the analysis. There is potential to link data-
bases of intravitreal therapy for neovascular AMD and systemic disease
at a national level in countries with comprehensive national registries.
Similarly, registries can be linked to assess ophthalmic safety out-
comes. In a clinical trial setting, regular intravitreal anti-VEGF injec-
tions have been associated with a sustained rise in intraocular pressure
in some patients (Bressler et al., 2015). A Canadian group postulated
that sustained elevated intraocular pressure could lead to higher rates
of glaucoma surgery. They performed a nested, case-control study and
analysed data from large, population-based, linked health databases in
British Columbia (Eadie et al., 2017). Study participants included all
patients in the Provincial Retinal Diseases Treatment Program who had
received intravitreal bevacizumab injections for neovascular AMD be-
tween 2009 and 2013. Cases were identiﬁed using glaucoma surgical
codes. For each case, 10 controls were identiﬁed and matched for age,
pre-existing glaucoma, and duration of follow-up. The number of in-
travitreal bevacizumab injections received per year (3 or fewer, 4 to 6,
or 7 or more) was determined for both cases and controls. Rate ratios
were adjusted for some covariates. There were 74 cases of glaucoma
surgery and 740 controls identiﬁed, with a mean (SD) age of 81.3 (8.4)
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years for cases and 81.4 (7.9) for controls. The adjusted rate ratio of
glaucoma surgery among those who received 7 or more injections per
year was 2.48 (95% CI, 1.25–4.93). The adjusted rate ratio for those
who received 4 to 6 injections per year compared with those who re-
ceived 3 or fewer was 1.65 (95% CI, 0.84–3.23). The study suggested
that 7 or more intravitreal injections of bevacizumab annually is asso-
ciated with a higher risk of glaucoma surgery. While this is an inter-
esting observation, confounders need to be considered and further
studies will be required to provide independent veriﬁcation before
causation can be determined.
Large scale registries have the potential to identify small increases
in ocular or systemic risk that randomised controlled trials are not
powered to detect. Additionally, patients with comorbidities are more
likely to be included in registry studies than clinical trials. Registries
also have the beneﬁt of providing long-term follow-up to identify late
adverse events.
5.6. Use of real-world registries by regulatory authorities as an alternative
to phase 4 trials for new drugs
The number of therapies for neovascular AMD will increase in the
future with many new drugs with diﬀerent modes of action currently in
phase I, II and III clinical trials (Pecen and Kaiser, 2015). Real-world
outcomes studies can be used by regulatory authorities to assess the
generalisability of clinical trial results. Large-scale population-based
observational studies facilitate the assessment of eﬃcacy, safety and
resource utilisation in a real-world setting. Large real-world observa-
tional data sets can be accumulated more rapidly and in a less expensive
way than traditional phase 4 clinical trials. Also, the impact of multiple
variables can be assessed, which would otherwise be costly and cum-
bersome if tested for individually and, as demonstrated in section 4 of
this review, may allow for novel interactions to be identiﬁed. There is
the potential to use real-world outcomes to guide remuneration of high
cost drugs in the future.
The FDA has access to several big data sources, in particular from
the Sentinel Initiative (FDA's electronic system for monitoring safety of
medicines) and the Centers for Medicare and Medicaid Services (CMS,
payer systems), which together comprise health data for over 200
million people. The FDA intends to publish guidelines on use of real-
world data in regulatory submissions (Sherman et al., 2016). They
caution that “the conﬂuence of large data sets of uncertain quality and
provenance, the facile analytic tools that can be used by non-experts,
and a shortage of researchers with adequate methodologic savvy could
result in poorly conceived study and analytic designs that generate
incorrect or unreliable conclusions” (Sherman et al., 2016). They report
that it is important to distinguish two key elements of real-world evi-
dence. The ﬁrst is the setting in which evidence is generated, which
includes the population deﬁned by the data source as well as the spe-
ciﬁc methods used to collect and curate the data on that population.
The second is the methodologic approach used to conduct the research
(Sherman et al., 2016).
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